US20140378908A1 - Drug delivery device - Google Patents
Drug delivery device Download PDFInfo
- Publication number
- US20140378908A1 US20140378908A1 US14/480,359 US201414480359A US2014378908A1 US 20140378908 A1 US20140378908 A1 US 20140378908A1 US 201414480359 A US201414480359 A US 201414480359A US 2014378908 A1 US2014378908 A1 US 2014378908A1
- Authority
- US
- United States
- Prior art keywords
- treatment
- drug
- injection
- drug delivery
- pen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000012377 drug delivery Methods 0.000 title description 129
- 238000011282 treatment Methods 0.000 claims abstract description 294
- 238000002347 injection Methods 0.000 claims abstract description 165
- 239000007924 injection Substances 0.000 claims abstract description 165
- 230000003285 pharmacodynamic effect Effects 0.000 claims abstract description 23
- 239000012530 fluid Substances 0.000 claims description 21
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 abstract description 174
- 229940079593 drug Drugs 0.000 abstract description 173
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 114
- 239000000126 substance Substances 0.000 abstract description 62
- 102000004877 Insulin Human genes 0.000 abstract description 57
- 108090001061 Insulin Proteins 0.000 abstract description 57
- 229940125396 insulin Drugs 0.000 abstract description 57
- 238000000034 method Methods 0.000 abstract description 26
- 210000001519 tissue Anatomy 0.000 description 59
- 239000008280 blood Substances 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 27
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- 230000000638 stimulation Effects 0.000 description 21
- 230000007246 mechanism Effects 0.000 description 18
- 206010047141 Vasodilatation Diseases 0.000 description 16
- 230000024883 vasodilation Effects 0.000 description 16
- 238000010438 heat treatment Methods 0.000 description 15
- 239000007788 liquid Substances 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 9
- 230000008081 blood perfusion Effects 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 230000001976 improved effect Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 230000000202 analgesic effect Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000005670 electromagnetic radiation Effects 0.000 description 5
- 230000005291 magnetic effect Effects 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000005684 electric field Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000008904 neural response Effects 0.000 description 4
- 206010033675 panniculitis Diseases 0.000 description 4
- ORMNNUPLFAPCFD-DVLYDCSHSA-M phenethicillin potassium Chemical compound [K+].N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C([O-])=O)=O)C(=O)C(C)OC1=CC=CC=C1 ORMNNUPLFAPCFD-DVLYDCSHSA-M 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 210000004304 subcutaneous tissue Anatomy 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000010304 firing Methods 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 229940090046 jet injector Drugs 0.000 description 3
- 230000003040 nociceptive effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 229960002504 capsaicin Drugs 0.000 description 2
- 235000017663 capsaicin Nutrition 0.000 description 2
- -1 for example Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- BFCDFTHTSVTWOG-YLJYHZDGSA-N (1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol Chemical compound CCCCCCCCN[C@H](C)[C@@H](O)C1=CC=C(SC(C)C)C=C1 BFCDFTHTSVTWOG-YLJYHZDGSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010062315 Lipohypertrophy Diseases 0.000 description 1
- 102000016261 Long-Acting Insulin Human genes 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 description 1
- 108010025083 TRPV1 receptor Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940127560 insulin pen Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229960001132 naftidrofuryl Drugs 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960003967 suloctidil Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 229940110851 tolazine Drugs 0.000 description 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/158—Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/16831—Monitoring, detecting, signalling or eliminating infusion flow anomalies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/19—Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M5/2448—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic comprising means for injection of two or more media, e.g. by mixing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/08—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by means of electrically-heated probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B18/1477—Needle-like probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/12—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
- A61B18/14—Probes or electrodes therefor
- A61B2018/1405—Electrodes having a specific shape
- A61B2018/1425—Needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
- A61F7/007—Heating or cooling appliances for medical or therapeutic treatment of the human body characterised by electric heating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/158—Needles for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body
- A61M2005/1581—Right-angle needle-type devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
- A61M2005/1726—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure the body parameters being measured at, or proximate to, the infusion site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
- A61M2205/052—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/054—General characteristics of the apparatus combined with other kinds of therapy with electrotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/057—General characteristics of the apparatus combined with other kinds of therapy with magnetotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/058—General characteristics of the apparatus combined with other kinds of therapy with ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
- A61M5/422—Desensitising skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
Definitions
- the present invention relates to systems and methods for delivering drugs to a patient.
- the present invention relates to systems and methods for subcutaneous injection of a medicament and using one or more treatment sources to improve effectiveness of the injected drugs.
- Pen injectors are useful when regular injection by persons without formal medical training occurs. This is increasingly common amongst those having chronic conditions such as diabetes where self-treatment enables such persons effectively manage their condition. Many of the insulin pen injectors are reusable and usually loaded with an insulin cartridge that may be used for a plurality of injections or for a number of days. Many other diabetic patients use regular syringe(s) and needles for insulin injection.
- Diabetes is a very serious illness affecting millions of people today. Many diabetic patients require injections of insulin to maintain proper levels of glucose in their blood in order to survive. Such injections of insulin require drug injection systems.
- Many medical treatment systems and methods involve drug injection systems that employ subcutaneous injections of therapeutic fluids, drugs, proteins, and other compounds.
- Such delivery systems and methods may use injection pens to inject insulin to the subcutaneous tissue, or regular syringe.
- the pen includes a disposable insulin reservoir and a disposable needle through which insulin is injected into the tissue.
- the needle is a single use needle, while the insulin reservoir can be used for two to three days.
- the injection is done by attaching the insulin injection pen to the skin at the injection site and pressing a button that first insert the needle using a spring into the subcutaneous tissue and then inject the insulin to the subcutaneous tissue.
- the patients require insulin injection around the clock to keep proper levels of glucose in their blood.
- Two major types of insulin can be injected—a long-acting insulin that provides the basal insulin rate needed for keeping patient's blood glucose in the desired range between meals and over night and an insulin bolus injection that provides an amount of insulin for matching a dose of carbohydrates consumed by the patient.
- the present invention relate to systems, devices and methods for injecting a drug, substances and/or chemicals to a patient that further provides a tissue treatment element for improving the effectiveness of drug delivery upon injection.
- the present invention relates to a device for improving performance of drug delivery in the form of injection pens or syringes.
- the present invention's suggested methods and devices can be used in many drug injection devices, such as injection pen(s), syringe(s), or jet injector(s), or other injection devices.
- injection pen(s), syringe(s), or jet injector(s) or other injection devices.
- the present application discusses mainly injection pens, it is understood by one skilled in the art that such devices can be used with any other injection devices.
- the present invention provides for a device that further provides an additional treatment to a tissue region where the drug is delivered.
- the treatment is utilized to improve drug delivery process by improving the drug's pharmacokinetic and/or pharmacodynamic profile.
- the treatment may come in various forms, for example, including analgesic, vasodilator or the like.
- the treatment may be any form of treatment that leads to improved vasodilatation of the tissue being injected, including but not limited to, exposing the tissue region to an energy, radiation, heat, mechanical vibrations, suction, massaging, acoustic stimulation, electromagnetic radiation, electric field, magnetic field, electrical stimulation, injection of an additional substance(s), or any combination of the above to improve the drug's pharmacokinetic and/or pharmacodynamic profile.
- Each treatment type may have a separate protocol in order to evoke the necessary reaction such as vasodilatation or the like.
- the present invention provides a needle free drug delivery pen that is coupled to a treatment element.
- the treatment element improves the pharmacokinetic and/or pharmacodynamic properties of the drug that is being delivered to the target tissue using a fluid jet.
- the drug delivery injector for administering a drug, for example, insulin, as a jet nozzle configured for firing insulin in a fluid jet in a configuration and with sufficient velocity to penetrate tissue of the patient to a delivery site.
- a drug containing compartment is associated with the nozzle for containing the drug and feeding the insulin to the delivery nozzle for injection.
- a firing mechanism includes an energy source is associated with the drug compartment for forcing the drug through the nozzle at a sufficient velocity to penetrate to the target site.
- the energy source producing the fluid jet can be a coil spring, gas spring, or any other spring.
- a trigger or a dosage release button of the drug delivery injector is movable by the user and associated with the firing mechanism for activating the energy source that produces the drug fluid jet by forcing of the drug through the nozzle once the release button is activated.
- the applied treatment induces vasodilatation through neural stimulation of the tissue of the drug injection site.
- the neural stimulation can be induced by thermal stimulation and/or mechanical stimulation and/or chemical stimulation.
- the human neural response to the thermal stimulation includes several mechanisms such as the Nociceptive Axon Reflex that induce vasodilatation among other effects.
- the induced neural response such as the Nociceptive Axon Reflex
- the induced neural response also induces widening of the capillary pores and increasing the capillary wall permeability. This effect is also significant for improving the absorption of the drag through the capillary wall.
- the applied treatment may lead to a reduction in the variability of the drug absorption in the blood or lymph system and its local and systemic effects.
- heating the tissue region in the vicinity of the area of drug delivery to a preset regulated temperature during and/or after the drug injection and absorption into the blood may cause local blood perfusion at that region to become more reproducible and the drug absorption process more uniform and reproducible as well.
- the variability of drug action induced by the delayed profile can be reduced.
- the temperature of the region adjacent to the injection region can be regulated for longer periods, but the cost may be the energy source volume and weight.
- the heating period or heating temporal profile can be optimized in relation to the period of the drug injection and absorption into the blood.
- the treatment utilized is, for example, heat
- the drug interaction with the treatment substance or type will be taken into consideration and can be avoided.
- a drug's temperature sensitivity will be accounted for so as to avoid protein denaturisation.
- Insulin is a temperature-sensitive protein and to avoid damage to the insulin the treatment protocol, heating can be limited to ensure the efficacy of the delivered drug.
- the treatment protocol may control the temperature or the location of the treatment delivery site so as to not damage the drug.
- the neural response that induces vasodilatation is stimulated by applying a mechanical force in the vicinity of the drug infused region, wherein the force includes, but is not limited to, one or more of the following: pressure, massage, vibration, suction and/or any other mechanical stimulation.
- tissue treatments or stimulations are known to stimulate the Nociceptive Axon Reflex as well.
- the mechanical stimulation is the fact that it does not damage the drug, whereas for example heating insulin above 37° C. may cause damage to it.
- the calibration of the applied mechanical force may be performed by using one of the procedures discussed above.
- an additional fluid substance can be combined with the drug or, alternatively, injected, infused, or topically applied (which may include transdermal delivery of the drug by permeating through the skin of the patient) to the drug injection site, such that the additional substance induces neural stimulation that leads to local vasodilatation and/or increases of the capillary permeability.
- the substances can include tolazine, naftidrofuryl, suloctidil, nitroprusside, capsaicin, or any other suitable substance.
- an additional substance may induce vasodilatation and improve blood perfusion in the drug infused tissue region. For example, capsaicin stimulates a neural response through the VR1 receptor and produces a similar response to thermal neural stimulation.
- the treatment element can be an integral part of the drug delivery injection pen, according to some embodiments of the present invention.
- the treatment element can be an auxiliary unit that may be interchanged, replaced, or added to an existing drug delivery injection pen.
- Such a device can be attached to the drug delivery pen either during or before the drug injection or applied to the drug injection site afterward.
- the treatment element may be any one or more of (or a combination of): a heating element, a radiation emitter, a sound transducer, a mechanical/electo-mechanical vibration device, a light emitting device, and an electrode.
- one or more of properties relating to the treatment element may be controlled by a processor in order to achieve a desired response of the tissue region undergoing drug delivery.
- properties include amplitude, phase, frequency, combination of excitation sources, relative ratio and timing between various excitation sources, or any other properties.
- the treatment type or sources can be also adjusted according to chemical and/or physical properties of the drug being delivered.
- the tissue response to the treatment element/stimulation enhances the functionality of the injected drug by enhancing the kinetics of molecular transport from the injection site inside the tissue to various compartments surrounding the tissue region and to the blood system.
- a treatment element or device supplying tissue treatment or stimulation to a tissue region can be configured to monitor and control properties of the treatment source.
- controllable properties of a treatment protocol include amplitude, phase, intensity, frequency, or any other properties.
- Further control can be gained by actively monitoring, such that the information is provided to a controller (“controller” or “processing unit”) that uses the information to reduce the variability of the drug pharmacokinetics.
- the device can be configured to monitor properties of the adjacent tissue, such as local blood perfusion or skin temperature. Based on such monitoring, the information can be provided to the controller that utilizes the information to improve pharmacokinetic or pharmacodynamic profile of the drug as well as its performance and reduce variability of the drug injection process.
- the present invention's device includes a sensor or other triggering input mechanism that is configured to prevent deployment of the drug delivery pen unless certain criteria are fulfilled. Such criteria can include activation of a treatment protocol or element.
- tissue treatment can be applied simultaneously with each injection of the drug delivery.
- the tissue treatment or stimulation option may be selected manually by the user.
- the user may choose to attach the treatment element to the drug delivery pen.
- the user can enable or disable mechanically the automatic application of treatment element.
- the user can activate the treatment device or devices before or after the drug injection to enhance the tissue response to the injected drug. Such activation can be done by pressing a button or a sequence of buttons on the drug delivery pen.
- the pen may have a special button for triggering a “fast bolus” as compared to regular bolus injection provided by the drug delivery injection pen.
- the fast insulin bolus mode can be configured to start one of the above treatments parallel to the injection of insulin or short time before or after the injection of the insulin bolus for a given period of time. This improves or modifies pharmacokinetics or pharmacodynamics of insulin administration, tissue blood perfusion and/or absorption in the blood of a patient and is highly advantageous when applied in conjunction with high glycemic index foods.
- Application of a “fast bolus” may be useful for consumption of high glycemic index foods, where larger rapid glucose excursions occurs, but also in most of the cases of using insulin boluses for prandial coverage.
- application of a “fast bolus” can be set as the default mode of the drug delivery pen.
- the user may apply the tissue treatment or stimulation before the meal to further increase the treatment effect.
- At least one effect of the treatments is to reduce local irritation caused by the infused drug or local inflammation reaction caused by the injection. For example, in case of insulin injection, reducing the period in which the high concentration of insulin remains in the tissue may reduce irritation that may be caused by insulin. It can also reduce unwanted effects of the insulin delivery, such as, lipohypertrophy.
- Some embodiments of the present invention also provide methods for improving or modifying a drug's pharmacokinetic or pharmacodynamic profile in order to reduce time to peak action in the blood of the injected material by applying a modulation pattern to the infused drug. With this modulation, the injection drug fluid is slightly moved/pulled in and out of the tissue during or after the drug injection process. In such embodiments, this method may not require an additional device applied to the skin.
- the drug delivery pen can mechanically attach a small disposable device to the skin either before, during or after delivery of the drug.
- the disposable device can apply a treatment or treatments using at least one of the following sources: a heat source (such as a heat resistor), a suction port, for example activated by a pump, a mechanical vibration source, an ultrasound excitation source, an ultrasound transducer, a light source, a massaging element, electromagnetic radiation source, electric field source, magnetic field source, additional substance and/or a combination of at least two of sources to improve drug pharmacokinetics.
- the small disposable device can be attached manually either before or after injection of the drug.
- a device for drug injection includes a disposable injection needle for injecting drug into tissue, a reusable drug delivery pen for inserting the needle into the patient skin or subcutaneous layer and for injection of the drug through the needle into one of the skin and/or subcutaneous tissue layer, a treatment device for applying a specific treatment or stimulation to the drug injected region in order to improve drug's pharmacokinetic, pharmacodynamic profile and/or to increase blood perfusion in that region before, during and/or after the drug injection period to improve drug absorption into the blood system.
- the needle can be injected automatically at the target site using an automatic needle triggering piston or spring. In some embodiments, the needle can be injected at the target site manually through the action of the user inserting the needle independently.
- a device for drug injection includes an injection catheter for insertion into the tissue, a drug injection device for infusing a drug into the injection catheter, a treatment device for applying a specific treatment or stimulation to the drug infused region in order to improve, modify and/or stabilize the drug pharmacokinetics, pharmacodynamics, and/or to reduce variations of the drug absorption into the blood system.
- a device for drug injection includes at least one of the following: a display, a button, a memory for boluses, a processing unit, a sensor for skin properties, a sensor for treatment level, a glucose sensor, a user interface, wireless connection to a PDA or cell phone for having memory and reminders and remote access to support sites.
- the device for drug/insulin injection includes a glucose sensor.
- the glucose sensor may measure blood glucose level at alternate sites (for example, at sites with reduced blood perfusion, such as arms and legs).
- the glucose sensor can be provided on the opposite side the injection end.
- the present invention can be configured for a jet injection. Jet injection involves high pressure injection of material, which obviates the use of needles. This type of injection mode is also referred to as “needle free” or “needleless” injection.
- the pen injection device can include a jet injection, in addition to or in place of, the use of one or more needles.
- needle-free injection systems include the Medi-Jector VISION® and some products by Antares. Such systems can be adapted for use with the present invention's jet injection system.
- the injection device includes a disposable nozzle and a reservoir having an additional substance.
- the reservoir is located at the nozzle and the additional substance is provided in a single use or single dose amount.
- the reservoir is located within the body of the device and the nozzle features a connector for fluid or other communication with the reservoir.
- an applicator for an additional substance is provided that is attached to or separate from the device.
- the nozzle can be disposed along with a gauge for adjusting the amount of additional substance to be applied.
- the applicator may be controlled through a button or other control component.
- the gauge can be configured as a ring that can be rotated around the applicator button or other control device to adjust the amount that the button is pressed and/or some function of the other control device and/or to adjust the dose of applied additional substance.
- the drug delivery pen can include an adhesive material, such as a sticker, for assisting the user to create a skin fold for administration of the drug and/or additional substance.
- an adhesive material such as a sticker
- FIGS. 1A-E illustrate an exemplary drug delivery pen combined with a mechanism for topical application of an additional substance to the drug injection site, according to some embodiments of the present invention.
- FIGS. 2A-C illustrates an exemplary drug delivery pen combined with a mechanism for topical application of an additional substance to the drug injection site, according to some embodiments of the present invention.
- FIGS. 3A-C illustrates an exemplary drug delivery pen combined with a mechanism for topical application of an additional substance to the drug injection site, according to some embodiments of the present invention.
- FIGS. 4A-D illustrates an exemplary drug delivery pen combined with a mechanism for topical application of an additional substance to the drug injection site, according to some embodiments of the present invention.
- FIGS. 5A-C illustrates an exemplary drug delivery pen combined with a mechanism for application of a treatment element on the drug injection site, according to some embodiments of the present invention.
- FIGS. 6A-C illustrates an exemplary drug delivery pen combined with a mechanism for application of a treatment element on the drug injection site, according to some embodiments of the present invention.
- FIGS. 7A-C illustrates an exemplary drug delivery pen and cover combined with a mechanism for application of a treatment element on the drug injection site, according to some embodiments of the present invention.
- FIGS. 8A-D illustrates an exemplary drug delivery pen combined with a mechanism for application of a treatment element on the drug injection site, according to some embodiments of the present invention.
- FIGS. 9A-C illustrates an exemplary drug delivery pen combined with a mechanism for application of a treatment element on the drug injection site, according to some embodiments of the present invention.
- FIGS. 10A-F illustrates an exemplary treatment element that may be coupled to a drug injection at the drug injection site, according to some embodiments of the present invention.
- FIGS. 11A-E are block diagrams of exemplary drug delivery devices, according to some embodiments of the present invention.
- FIGS. 12A-C illustrate an exemplary drug delivery pen combined with a mechanism for application of a treatment element on the drug injection site, according to some embodiments of the present invention.
- FIG. 13 is a flow chart illustrating an exemplary method for controlling temperature of heating that is provided by a treatment element in order to prevent degradation of a temperature sensitive drug.
- the present invention relates to a drug delivery pen or other drug injection devices for the injection of a drug at a drug injection site, where the drug in injection device applies a treatment that can improve injected drug's pharmacokinetic and/or pharmacodynamic properties.
- the following description will refer to a drug injection pen for illustrative, non-limiting purposes, however, as can be understood by one skilled in the art, the present invention is applicable to any other drug injection devices.
- FIGS. 1A-C are schematic diagrams of an exemplary drug delivery pen 100 having a treatment element coupled to the delivery pen, according to some embodiments of the present invention.
- FIG. 1A is a perspective view of the drug delivery pen 100 .
- FIG. 1B is a side view of the pen 100 .
- the drug delivery pen for the delivery of insulin, may function as do state of the art drug delivery pens by injecting the selected and determined drug dosage 106 and using injection piston release button 112 to release the piston (not shown) that presses and/or otherwise places pressure on the drug reservoir syringe or vial, for causing injection of the required dosage of drug (not shown) into the targeted area and through needle housing 102 .
- a fluid jet of the delivered drug can be utilized instead of a syringe to delivery the drug through housing 102 to the targeted delivery site.
- the drug delivery pen can provide an additional treatment element, such as, an anesthetic, a drug for inducing treatment, a drug for improving effectiveness of the primary drug being injected.
- the primary drug can be insulin.
- FIG. 1C is a cross-sectional view of the drug delivery pen 100 showing the treatment element 130 and components thereof.
- Treatment element 130 includes treatment compartment 120 , a plurality of valves 122 , a pump 126 and a treatment release button 128 .
- the treatment compartment 120 stores a formulation of a liquid, ointment, solution, aerosol, foam, solid, gel foam, pressurized liquid, gas, spray, pain reliever drug, analgesic, vasodilatation drug, septic, alcohol, or the like for treatment of the skin tissue area.
- treatment may be applied prior to or following deployment of the needle.
- Treatment substance stored in compartment 120 can be pumped to the treatment release openings 104 using schematic pump 126 that is activated by pressing treatment release button 128 .
- the treatment release button 128 releases valves 122 to deliver treatment liquid from the compartment 120 through the tube 124 that leads to openings 104 .
- the treatment applied to an area can lead to improved pharmacokinetic and/or pharmacodynamic properties of the primary drug being delivered by way of injection.
- the pathway by which the pharmacodynamic and/or pharmacokinetic properties of the drug are improved may be dependent on the treatment substance or element utilized.
- FIG. 1D is a partial exploded view of a drug delivery pen 140 having a manual injection portion 141 , according to some embodiments of the present invention.
- Pen 140 includes a pen body 150 , a dosage release button 142 , a treatment release button 148 , a drug dosage selector 146 , and an injection coupling portion 144 .
- Injection coupling portion 144 is a connection mode to securely affix injection portion 141 to the pen portion 140 .
- the coupling of the injection portion 141 to the pen portion 140 may be accomplished by at least one or more connecting pieces, such as, male/female connectors, threaded connectors, snap connector(s), turn key connectors, hook connectors or any other suitable connectors.
- Manual injection portion 141 includes a treatment substance reservoir 152 , a treatment delivery opening 154 and a needle 158 .
- the manual injection portion 141 can be disposable after a single use. However, the injection portion 141 can be reusable and can be used a number of times or repeatedly over a period of time.
- Prior to drug delivery the drug delivery pen body 150 is securely coupled to manual injection portion 141 allowing a user to use the drug delivery pen 140 by selecting a drug dosage using dosage selector 146 .
- Treatment release button 148 triggers the release of the treatment substance from the treatment reservoir 152 through delivery openings 154 .
- the timing of treatment release can be performed prior to, during or following drug delivery, or in a combination thereof.
- Drug delivery can be accomplished by setting the dosage amount using dosage selector 146 , manually inserting needle 158 into the target site, releasing treatment substance through delivery openings 154 and finally delivering the drug with dosage release button 142 .
- FIG. 1E depicts an additional optional embodiment of the manual drug delivery pen of FIG. 1D .
- Manual drug delivery pen includes a drug delivery pen housing 160 and manual injection portion 161 .
- Pen housing 160 includes a pen body 170 , a dosage release button 162 , a drug dosage selector 166 , a treatment release button 168 , a treatment dosage selector 178 , a treatment substance tube 176 , and an injection coupling portion 164 .
- the injection coupling portion 164 can be configured to securely affix injection portion 161 to the pen body portion 160 . Coupling of the injection portion 161 to pen portion 160 can be accomplished by at least one or more connecting pieces, such as, a male to female connector(s), threaded connectors, snap connector(s), turn key connector(s), hook connectors or any other connection devices.
- Manual injection portion 161 is disposable for single use, however, injection portion 161 may be used a number of times, or repeatedly over a continuous period of time.
- the drug delivery pen body 170 Prior to drug delivery the drug delivery pen body 170 is securely coupled to manual injection portion 161 allowing a user to use drug delivery pen 160 by selecting a drug dosage using drug dosage selector 166 .
- Treatment dosage selector 178 determines the dosage of the treatment substance to be released with treatment release button 168 . Pressing treatment release button 168 triggers the release of the treatment substance from the treatment reservoir (not shown) through at least one or more treatment delivery tube 176 that ends in treatment delivery openings 174 . Timing of treatment dosage selection and release may be performed prior to, during or following drug delivery, or in a combination thereof.
- Drug delivery is accomplished by setting the dosage amount using dosage selector 166 , manually inserting needle 158 into the target site, releasing treatment substance through delivery openings 174 as described above and finally delivering the drug with dosage release button 162 .
- FIGS. 2A-C illustrate an exemplary drug delivery pen according to the present invention which is similar to the embodiments depicted in FIGS. 1A-C .
- the treatment opening is on the opposite side of the needle housing.
- FIG. 2A is a perspective view of the drug delivery pen 200 .
- FIG. 2B is a side view of pen 200 .
- the drug delivery functions in a similar fashion as some conventional pens, such as NovoPen, FlexPen, Sanofi Aventis pens or the like, by setting the determined drug dosage 206 and pressing an upper button (not shown in FIGS. 2A-C ) that pushes the syringe piston (not shown in FIGS. 2A-C ) at the required distance to inject the dosage that was set, such that injection release button 208 is not required.
- the drug is injected by releasing the injection release button 208 which releases the piston (not shown in FIGS.
- the drug delivery pen provides an additional treatment element, such as, in the form of another drug, to induce a treatment for improving the primary drug being injected.
- the above injection pen's configuration and mechanism as well as other injection devices, such as syringes or jet injectors, can be configured to be used with devices and methods for applying additional treatment to the vicinity of the drug injection site, as described by the present and related applications.
- the primary drug can be insulin.
- FIG. 2C is a cross-sectional view of drug delivery pen 200 showing the treatment element 230 and components thereof.
- Treatment element 230 includes a treatment compartment 220 , a plurality of valves 222 , a pump 226 , a treatment tube 224 and a treatment release button 228 .
- the treatment compartment 220 stores a formulation, a fluid, such as a liquid, ointment, solution, aerosol, pressurized liquid, gas, spray, pain relieve drug, analgesic, vasodilatation drug, septic, alcohol, or the like for treating the skin tissue area.
- the treatment may be applied prior to or following deployment of the needle, in a two step process one end of the pen for substance treatment delivery using opening 204 and the opposite end for the injection using housing 202 .
- a treatment substance stored in the compartment 220 can be pumped to the treatment release openings 204 using schematic pump 226 that is activated by pressing the treatment release button 228 .
- the treatment release button 228 releases valves 222 to deliver treatment liquid from the compartment 220 through the tube 224 that leads to the openings 204 .
- the treatment applied to an area may lead to improved pharmacokinetic and/or pharmacodynamic properties of the primary drug being delivered by way of an injection.
- the pathway by which the pharmacodynamic and/or pharmacokinetic properties of the drug are improved may be dependent on the treatment substance or element utilized.
- FIGS. 3A-C illustrate an exemplary pen-type drug delivery device similar to that described in connection with FIGS. 1A-E and 2 A-C, however, in this case, the treatment substance is applied by way of a roller-applicator ball 304 onto the tissue being treated.
- FIGS. 3A and 3B illustrate similar views of drug delivery pen 300 .
- the drug delivery function of pen 300 is similar to the functions of pens shown in FIGS. 1A-E and 2 A-C.
- the drug dosage can be controlled and determined using a dosage dial 306 that is delivered via the needle housing 302 that encloses a needle (not shown in FIGS. 3A-C ), which is triggered using an injection release button 312 .
- a treatment substance may be applied to the injected area either prior to or following injection.
- FIG. 3C depicts treatment element 330 including treatment substance container 320 and substance application ball 304 .
- the treatment compartment 320 stores a fluid, such as, a liquid, ointment, solution, aerosol, pressurized liquid, gas, spray, pain relieve drug, analgesic, vasodilatation drug, septic, alcohol, or the like for treating the skin tissue area.
- Treatment may be applied with a ball 304 prior to or following deployment of the needle, in at least a two-step process one end of the pen for substance treatment delivery using ball 304 the opposite end for the injection using housing 302 .
- FIGS. 4A-C illustrate another exemplary drug delivery pen 400 , according to some embodiments of the present invention.
- Treatment substance 430 used to improve the pharmacokinetic and/or pharmacodynamic properties of the drug being delivered may come in the form of a solid, gel, gel form, thixotropic solution or the like.
- the substance 430 may be applied to a treatment area either prior to or following drug delivery using a needle delivered through needle housing 402 .
- the treatment substance 430 can be a solid, stick, ointment, solution, pain relieving drug, analgesic, vasodilatation drug, septic, alcohol, or the like to treat the skin or tissue area.
- Substance treatment 430 can be rubbed, rolled over the treated area or applied in any other suitable way.
- the drug delivery pen 400 may be manufactured separately from the individual treatment substance 430 ; alternative, the drug delivery pen 400 may be manufactured along with treatment substance 430 being coupled thereto.
- FIG. 4D depicts the treatment substance 430 that can be configured to fit over the pen shaft 410 using a sticker, a threading, an adhesive layer, a clip, or any other coupling tools.
- the pen shaft 410 can be pushed through the lumen of treatment substance 430 .
- the treatment substance 430 can be configured to fit circumferentially around the pen shaft 410 .
- a single use or a reusable treatment substance 430 can be used with other drug injection devices, such as a syringe.
- FIG. 5A illustrates an exemplary drug delivery injectable pen having a needle housing that can accept secondary devices for substance treatment deployment or use, according to some embodiments of the present invention.
- Drug delivery pen 500 includes shaft 510 that is configured to contain a volume of the injectable drug (such as insulin) for delivery.
- a dosage dial 506 sets the dosage to be injected with a needle that is injected via an injection release button 520 through the needle and the needle housing 502 .
- the drug delivery pen 500 includes a glucose sensor 501 for measuring blood glucose with a finger stick.
- Glucose sensor 501 can be configured to be on the top of the drug delivery pen 500 .
- the pen 500 can be used to release a needle that is used to draw a drop of blood that may be placed over a finger stick (not shown in FIGS. 5A-C ) and is placed over the glucose sensor 501 for reading the glucose levels in the drawn blood sample.
- the drop of blood can be applied to a finger stick like glucose sensor inserted into a glucometer type slit, for example on the top of pen 500 (not shown in FIGS. 5A-C ).
- FIG. 5B depicts a treatment element apparatus 530 that may be coupled to the drug delivery pen 500 , as shown in FIG. 5C , to form drug delivery apparatus 540 .
- the drug delivery apparatus 540 including the treatment element apparatus 530 and drug delivery pen 510 may be single unit.
- the treatment element apparatus 530 includes a female connector 524 that can be securely coupled to the needle housing 502 , which has a corresponding male connector shape.
- the coupling can be undertaken by threading, fitting, pin lock assembly, adhesives or any other coupling methods.
- the drug delivery pen 530 includes treatment substance dispenser 520 that contains a roll 520 adhered to a plurality of treatment element 526 .
- the treatment element 526 can be securely placed over the end of needle housing 502 .
- the treatment element 526 can be implemented in the form of a pad (e.g., releasing an additional substance), a heating pad, a PCB heating element, an optical treatment element, an electromagnetic radiation treatment element, an electrical current treatment element, an acoustical treatment element, a massaging treatment element or an element related to any of the treatment methods discussed above.
- the treatment element 526 can deliver treatment to a target tissue prior to injection, following injection, or at the time of injection to improve the pharmacodynamic and/or pharmacokinetic properties of an injectable drug.
- Treatment element 526 can also include a power source to provide the desired treatment power.
- Treatment element can include a control element, such as an electrical circuit, to control the treatment profile.
- Treatment element can be disposable, e.g., single use treatment element, whereby after the treatment profile ends, the user can dispose of the treatment element 526 .
- Treatment element can be reusable, whereby after the treatment profile ends, the user can recharge it, exchange the power source, or exchange only a portion of the treatment element 526 that is disposable and then reload it into a new or the same treatment substance dispenser 520 or a substance dispenser 630 shown in FIG. 6A or any other configuration, as disclosed in the present application.
- FIGS. 6A-C illustrate exemplary treatment element dispensers that may be coupled to a drug delivery pen 500 , as illustrated in FIG. 5A .
- FIG. 6A illustrates a treatment dispenser 630 that is an optional alternative to dispenser 530 of FIG. 5B .
- Treatment dispenser 630 includes stackable treatment elements 626 that may be coupled to the pen drug delivery device.
- FIG. 6B illustrates how a drug delivery pen is coupled to the treatment element dispenser 630 .
- the needle end of the apparatus is coupled with a treatment element 626 .
- the treatment element 626 is alignable with the needle of drug delivery pen 650 . This alignment provides for a drug delivery and treatment apparatus 650 to induce application of treatment using element 626 prior to, following, or at the same time as undertaking drug delivery with the drug delivery pen 600 in a one step process.
- the drug delivery using the pen 600 and evoking treatment using element 626 may be undertaken in a two-step process, where treatment element 626 is coupled to a non-needle end of the drug delivery pen 600 .
- This allows drug delivery and treatment to be performed individually. For example, one can trigger the drug delivery with the injection release button 612 and later evoke treatment using element 626 . The reverse is also true where treatment may precede drug delivery.
- the treatment element such as treatment element 526 (shown in FIGS. 5A-C ) or element 626 , is coupled to a single use needle that is secured to the pen before each dose injection (as shown in FIGS. 1D and 1E ), such that when the needle is inserted into the body, the treatment element is attached to and/or otherwise adheres to or around the injection site, automatically, without the need of additional operations by the user.
- the treatment element may include an energy source, which can provide heat, radiation, mechanical vibrations, suction, magnetic energy, ultrasound, light irradiation, RF irradiation, microwave irradiation, electrical stimulation, or any other form of energy or combinations of those energy sources.
- an energy source which can provide heat, radiation, mechanical vibrations, suction, magnetic energy, ultrasound, light irradiation, RF irradiation, microwave irradiation, electrical stimulation, or any other form of energy or combinations of those energy sources.
- the treatment element may include a heater to heat the injection site; or a source of optical energy for the energy source, such as a light source, including but not limited to LEDs or laser diodes for example, with one or more other optical elements; or a micro-wave generator or emitter configured to irradiate the injected region with micro-wave radiation; or a radio frequency electromagnetic radiation generator or emitter configured to irradiate the injected region with radio frequency electromagnetic radiation; or a vibration device configured to vibrate the injected region; or a vacuum device for applying suction to the injected region; or an electric field generator or emitter configured to apply an electric field to the injected region; or a magnetic field generator or emitter configured to apply magnetic field to the injected region; or an acoustic signal generator or emitter configured to apply acoustic stimulation to the injected region.
- a source of optical energy for the energy source such as a light source, including but not limited to LEDs or laser diodes for example, with one or more other optical elements
- FIGS. 7A-C illustrates an exemplary drug delivery pen 700 similar to the pens shown in FIGS. 5A-C and 6 A-C, that is coupled to a treatment element dispenser 730 as shown in FIG. 7B to create drug delivery and treatment apparatus 750 .
- the apparatus 750 includes a treatment element dispenser 730 at the non needle end of drug delivery pen 700 .
- the apparatus 750 provides the drug delivery pen with an ability to deliver drug(s) in a chosen dosage while providing the treatment element that may improve the pharmacokinetic and/or pharmacodynamic property of the delivered drug.
- the user can store his/her treatment element(s) in a special case, or in the case of the drug injection device.
- the user inserts the treatment element, as discussed above, into the treatment element dispenser 730 and applies it to the injection site.
- the treatment element can have a similar shape as the treatment element dispenser 730 and can be coupled directly to the drug delivery pen 700 without using the treatment element dispenser as an adaptor.
- FIGS. 8A-D illustrate an exemplary treatment apparatus, similar to the one shown in FIGS. 1A-3C , according some embodiments of the present invention.
- FIG. 8A depicts a drug delivery pen 800 used to deliver an injectable drug.
- FIGS. 8B and 8C are views of the treatment element 830 that can be coupled to the drug delivery pen 800 , thus, forming a drug delivery and treatment apparatus, as shown in FIG. 8A .
- the treatment element 830 can be coupled to the pen 800 via the opening 840 that receives the needle end of the drug delivery pen 800 .
- Treatment element 830 includes a treatment substance compartment 820 that can be utilized to store treatment fluid.
- the treatment compartment 820 stores a fluid, such as gel, foam, liquid, ointment, solution, aerosol, pressurized liquid, gas, spray, pain relieve drug, analgesic, vasodilatation drug, septic, alcohol, or the like for treating the skin tissue area. Treatment can be applied prior to or following deployment of the needle.
- a fluid such as gel, foam, liquid, ointment, solution, aerosol, pressurized liquid, gas, spray, pain relieve drug, analgesic, vasodilatation drug, septic, alcohol, or the like for treating the skin tissue area. Treatment can be applied prior to or following deployment of the needle.
- Treatment liquid stored in the compartment 820 can be delivered to the target tissue through the opening 804 using pump 826 that is activated by pressing the treatment release button 828 .
- the treatment release button 828 releases valves 822 to deliver treatment liquid from the compartment 820 through the tube 824 that leads to the opening 804 .
- the amount of treatment liquid can be preset for a user.
- a special dial or other means (not shown in FIGS. 8A-D , but illustrated in FIG. 1E ), may be used to set the amount of applied treatment substance.
- the treatment applied to an area can lead to improved pharmacokinetic and/or pharmacodynamic properties of the primary drug being delivered by way of injection (e.g., insulin).
- the pathway by which the pharmacodynamic and/or pharmacokinetic properties of the drug are improved is optional and may be dependent on the treatment substance or clement utilized.
- FIGS. 9A-C illustrate the drug delivery pen 900 having the treatment element provide pressure-related treatment, such as suction, massage, or the like, according to some embodiments of the present invention.
- FIG. 9A depicts a drug delivery pen and treatment apparatus 950 including a drug delivery pen 900 and a treatment element attachment 930 that can be mechanically coupled.
- the apparatus 950 can be provided as an assembled or unitary drug delivery device.
- the apparatus 950 can be coupled to the treatment element 940 that is made from a pliable material that can withstand pressure. Such material can be rubber, latex, or any other suitable material configured to create suction over a given treatment area similar to a plunger.
- the apparatus 950 is placed over the treatment element 940 and is compressed to create further pressure, as shown in FIGS.
- Drug delivery deployment can be undertaken in the compressed form of the treatment element 940 , as shown in FIG. 9C .
- FIGS. 10A-D illustrate a variety of pressure based treatment elements, according to some embodiments of the present invention.
- FIG. 10A is a cross-sectional view of the treatment element shown in FIG. 10B .
- the treatment element can be used during drug delivery and includes a lumen 1000 allowing the needle to penetrate through.
- FIG. 10C is a cross-sectional view of the treatment element shown in FIG. 10D .
- the treatment element of FIG. 10D can be utilized either prior to or following drug delivery in order to create suction over the tissue area.
- the treatment elements of FIGS. 10A-D can be used to create suction or vacuum in the vicinity of the drug injection site and to induce local vasodilatation.
- FIGS. 10E and 10F illustrate an exemplary treatment element configured as a durable adhesive tape that is used to effectively pinch a fold of skin while maintaining its shape.
- the treatment element shown in FIG. 10E includes two sticky ends 1050 that are bridged by a malleable section 1052 . Each one of the ends 1050 is placed over a patch of skin where an injection for example with a syringe or a drug delivery pen is to be undertaken. Once in place, the ends 1050 are pushed toward each other by the malleable section 1052 to form a bell type shape.
- Section 1052 can be manufactured from a strong malleable material that can hold its shape, while being repeatedly formed and deformed.
- FIG. 10F depicts the treatment element of FIG. 10E in a folded form. Section 1052 can be moulded and reshaped forming a treatment element for example to bring about vasodilatation.
- FIG. 11A is a block diagram of an exemplary drug delivery apparatus 1100 having a treatment element 1102 incorporated into a drug delivery pen 1104 , wherein the treatment element is integrated into the drug delivery pen, according to some embodiments of the present invention.
- FIG. 11B is a block diagram of an exemplary drug delivery apparatus 1110 having a treatment element 1112 and a drug delivery device 1114 that are removably coupled to each other, according to some embodiments of the present invention.
- the drug delivery device 1114 or treatment element 1112 can function independently of one another and can be securely coupled to each other to form a single drug delivery and treatment apparatus 1110 , similar to the embodiment of FIGS. 4A-6C .
- Drug delivery device 1114 can be implemented as a syringe, drug delivery pen, drug delivery jet injector or the like.
- FIG. 11C is a block diagram of an exemplary drug delivery and treatment apparatus that further includes a sensor 1126 , such as a glucose stick sensor, for measuring blood glucose.
- the drug delivery apparatus 1120 communicates with an external processing unit 1130 .
- the processing unit can be a PDA, a cellular phone, a computer, a laptop or any other device.
- the unit 1130 includes a controller 1132 and a display 1134 .
- the controller 1132 controls analysis of data received from the drug delivery apparatus 1120 to determine treatment or dosage form or the like related to the functioning of drug delivery pen 1124 , and treatment element 1122 .
- the processing unit 1130 provides the user with data regarding historical and current use of the drug delivery apparatus 1120 .
- FIG. 11D is a block diagram of an exemplary drug delivery device similar to the device shown in FIG. 11C , where the drug delivery apparatus 1140 has an integrated sensor 1146 , a processing unit 1150 and a display 1148 , according to some embodiments of the present invention. This allows the user to fully control, visualize all activity related to the drug delivery pen 1144 or the treatment element 1142 .
- FIGS. 12A-C schematically illustrate exemplary treatment element dispensers that may be coupled to a drug injection device 1200 (as shown in FIG. 12C ), according to some embodiments of the present invention.
- FIG. 12A illustrates a treatment element 1210 with a power source 1211 .
- the treatment element 1210 includes a power source and a control element to control a treatment profile.
- treatment element 1210 can include a heater to heat the tissue around the injection site to a temperature that improves drug's pharmacokinetics and pharmacodynamics.
- treatment element 1210 can include a heater to heat the tissue around the injection site to a temperature that improves drug's pharmacokinetics and pharmacodynamics, without heating the drug above a limiting temperature that may degrade it, such as 37° C. in the case of some types of insulin.
- Treatment element 1210 may include also an adhesive layer on its bottom side covered with a laminate 1212 .
- the user has a case with one or few treatment elements 1210 .
- the user takes adaptor 1220 , which can be stored in the same case or a different one, and attaches one treatment clement 1210 to adaptor 1220 , as shown in FIG. 12B .
- Treatment element 1210 can be attached to adaptor 1220 with a weak mechanical locking, such as a plastic clip, or weak adhesive or other ways known in the art.
- laminate 1212 can be removed.
- adaptor 1220 is assembled or threaded over drug delivery pen or syringe 1230 , as shown at FIG. 12C .
- needle cap 1231 can be removed from the needle.
- the needle is inserted into injection site tissue, the drug injection device is operated and the drug is injected through needle into the tissue. During that time, or slightly before or after adaptor 1230 , is pushed down to the tissue and treatment element 1210 is attached to the tissue around drug injection site.
- the attachment of treatment element 1210 to the tissue is configured to activate it automatically and the treatment starts according to a predetermined treatment profile. This function can be performed, for example, by a small switch which is pressed when treatment element 1210 is attached to the tissue.
- the treatment element 1210 can be activated manually.
- treatment element can be controlled and/or programmed for a specific treatment element through a remote control or a connection to its case. Afterwards, the injection device 1230 and the adaptor 1220 are lifted off, either together or separately, and the treatment element 1210 is left attached to the tissue and applies treatment to the vicinity of the drug injection site. The user can remove treatment element after treatment ends or later on.
- the treatment element includes an indicator for the user that indicates the beginning of the treatment and the end of the treatment.
- the treatment element 1210 may be disposable.
- the treatment element's 1210 power source 1211 may be rechargeable, so that after the treatment ends and the user removes it from the skin, it can be put back to the case and/or placed in a charging cradle for recharging which may be disposed in said case.
- the treatment element 1210 may have a disposable portion and a reusable portion.
- the drug injection device and at least one treatment element are disposed in the same case prior to injection. This provides additional comfort for the user and allows the user to use both of them together or one after the other.
- FIG. 13 is a flow chart depicting a method for controlling the temperature of heating provided by a treatment elements that heat the injection site tissue vicinity in order to prevent degradation of a temperature sensitive drug.
- a drug is provided for injection to the patient, where the drug is sensitive to degradation above a limiting temperature.
- a treatment element is provided that features a controllable heating through a controllable heating element.
- the treatment element is placed in thermal contact with the tissue to be heated, such that heat from the treatment element is transferred to the tissue to be heated.
- a maximum temperature provided by the treatment element is controlled, such that the temperature experienced by the drug (that is, in the environment of the drug) does not exceed the limiting temperature sustainable by the drug before degradation occurs.
- he maximum temperature can be calibrated for each drug and/or class of drugs. For example, for some types of insulin, the limiting temperature is about 37° C.
- control can be provided through a microprocessor or other processor for controlling the temperature output by a heating element.
- a sensor can be provided in order to measure the temperature at and/or near the tissue being heated, in order to determine the temperature experienced by the drug.
- the treatment element includes one or more materials capable of generating an exothermic reaction, in which the amount of such materials and/or ratio can be calculated in order for the temperature of the reaction not to exceed the maximum temperature set for the treatment element based on the desired limiting temperature of the drug.
- the exothermic reaction can be a heat-generating oxidation reaction, for example, with a mixture of iron powder, activated carbon, salt and water. As can be understood by one skilled in the art, other such mixtures of materials can be used.
- the treatment element and the drug delivery pen are not disposed in the same housing. However, in such cases the user may forget to apply the treatment to the injection site in some cases, thereby changing the pharmacokinetics, which is undesirable. Therefore, to prevent that the drug delivery pen can include a mechanism for reminding the user to apply the required treatment, before, during or after injecting the drug into the tissue.
- the drug delivery pen includes a mechanism that identifies whether the treatment was applied or not and permits drug injection only when the tissue treatment was applied.
- the drug delivery pen includes, in addition to the drug injection mechanism, a sensor that indicates whether the treatment was applied or was not applied and a processing unit that enables injection of the drug only when the tissue treatment was applied. Such sensor can be an optical sensor that measures optical properties of the local tissue, or Laser Doppler Flowmeter (“LDF”) that can measure local blood perfusion and identify that the vasodilatation inducing local treatment was applied and that the treatment level was adequate.
- LDF Laser Doppler Flowmeter
- Example embodiments of the methods and components of the present invention have been described herein. As noted elsewhere, these example embodiments have been described for illustrative purposes only, and are not limiting. Other embodiments are possible and are covered by the invention. For example, at the present application many of the suggested methods and devices can be used for many of the drug injection devices, such as injection pens or syringes or jet injector and other known in the art injection devices, so although the examples are mainly given for injection pens they are applied to the other injection devices as well. Such embodiments will be apparent to persons skilled in the relevant art(s) based on the teachings contained herein. Thus, the breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
Abstract
The present disclosure presents systems, devices and methods for injection of drugs, substances and/or chemicals to a patient and for improving their effectiveness once they are injected are disclosed. Additional treatment can be applied to a tissue region on the patient into which a drug (e.g., insulin) is injected, to expose the tissue region to various forms of energy or a substance to improve the drug's pharmacokinetic and/or pharmacodynamic profile.
Description
- The present invention claims priority to U.S. Provisional Patent Application No. 60/895,518, filed Mar. 19, 2007, U.S. Provisional Patent Application Ser. No. 60/895,519, filed Mar. 19, 2007, U.S. Provisional Patent Application Ser. No. 60/912,698, filed Apr. 19, 2007, U.S. Provisional Patent Application Ser. No. 60/940,721, filed May 30, 2007, U.S. Provisional Patent Application No. 61/016,571, filed Dec. 25, 2007, U.S. Provisional Patent Application No. 61/008,277, filed Dec. 18, 2007 and U.S. Provisional Patent Application No. 61/010,758, field Jan. 10, 2008, and U.S. patent application Ser. No. 11/812,230, filed Jun. 21, 2007, the disclosures of which are incorporated herein by reference in their entireties.
- 1. Field of the Invention
- The present invention relates to systems and methods for delivering drugs to a patient. In particular, the present invention relates to systems and methods for subcutaneous injection of a medicament and using one or more treatment sources to improve effectiveness of the injected drugs.
- 2. Background of the Invention
- Pen injectors are useful when regular injection by persons without formal medical training occurs. This is increasingly common amongst those having chronic conditions such as diabetes where self-treatment enables such persons effectively manage their condition. Many of the insulin pen injectors are reusable and usually loaded with an insulin cartridge that may be used for a plurality of injections or for a number of days. Many other diabetic patients use regular syringe(s) and needles for insulin injection.
- Diabetes is a very serious illness affecting millions of people today. Many diabetic patients require injections of insulin to maintain proper levels of glucose in their blood in order to survive. Such injections of insulin require drug injection systems.
- Many medical treatment systems and methods involve drug injection systems that employ subcutaneous injections of therapeutic fluids, drugs, proteins, and other compounds. Such delivery systems and methods, especially for insulin delivery, may use injection pens to inject insulin to the subcutaneous tissue, or regular syringe. In the conventional insulin injection pens, the pen includes a disposable insulin reservoir and a disposable needle through which insulin is injected into the tissue. The needle is a single use needle, while the insulin reservoir can be used for two to three days. In the conventional insulin injection pens, the injection is done by attaching the insulin injection pen to the skin at the injection site and pressing a button that first insert the needle using a spring into the subcutaneous tissue and then inject the insulin to the subcutaneous tissue.
- In many instances, the patients require insulin injection around the clock to keep proper levels of glucose in their blood. Two major types of insulin can be injected—a long-acting insulin that provides the basal insulin rate needed for keeping patient's blood glucose in the desired range between meals and over night and an insulin bolus injection that provides an amount of insulin for matching a dose of carbohydrates consumed by the patient.
- When patient consumes food, his or her levels of glucose rise. Unfortunately, many conventional subcutaneous injection devices are incapable of quickly matching and/or preventing the rise of blood glucose. The delay in such matching is also true in case of the “rapid-acting” insulin. Some of the reasons for this delay include a lag in the absorption of insulin from the injection site and the time it takes for complex insulin molecules to break down into monomers.
- Additionally, since blood glucose levels rise shortly following the meal, the delay in matching insulin to the rising levels causes post prandial hyperglycemic events (i.e., when levels of blood glucose are above normal) to occur. Occasionally, after certain period of time passes (e.g., 2-3 hours) after the meal, the blood glucose levels drop yet insulin concentrations in the blood rise followed by the peak of the systemic insulin effect and may result in causing hypoglycemic events (i.e., when levels of blood glucose are below normal) to occur. Both hyperglycemic and hypoglycemic events are highly undesirable. Additionally, since local blood perfusion at the insulin injection region has large variability, depending on the ambient temperature and other parameters, it induces large variations to the delay of the peak of time profile of the insulin action. Those variations in the insulin peak action period further increase the variability in the blood glucose level.
- Thus, it is desirable to provide a system and a method that provides efficient and rapid injection and absorption of the drug to the patient circulatory system. In particular, it is desirable to provide a system and a method for injection of insulin to the patient that improves effectiveness of insulin in the blood to maintain normal levels of blood glucose and prevent or reduce hyperglycemic and hypoglycemic events.
- The present invention relate to systems, devices and methods for injecting a drug, substances and/or chemicals to a patient that further provides a tissue treatment element for improving the effectiveness of drug delivery upon injection. In some embodiments, the present invention relates to a device for improving performance of drug delivery in the form of injection pens or syringes. In general, the present invention's suggested methods and devices can be used in many drug injection devices, such as injection pen(s), syringe(s), or jet injector(s), or other injection devices. As such, although the present application discusses mainly injection pens, it is understood by one skilled in the art that such devices can be used with any other injection devices. In some embodiments, the present invention provides for a device that further provides an additional treatment to a tissue region where the drug is delivered. In some embodiments, the treatment is utilized to improve drug delivery process by improving the drug's pharmacokinetic and/or pharmacodynamic profile. The treatment may come in various forms, for example, including analgesic, vasodilator or the like. The treatment may be any form of treatment that leads to improved vasodilatation of the tissue being injected, including but not limited to, exposing the tissue region to an energy, radiation, heat, mechanical vibrations, suction, massaging, acoustic stimulation, electromagnetic radiation, electric field, magnetic field, electrical stimulation, injection of an additional substance(s), or any combination of the above to improve the drug's pharmacokinetic and/or pharmacodynamic profile. Each treatment type may have a separate protocol in order to evoke the necessary reaction such as vasodilatation or the like.
- In some embodiments, the present invention provides a needle free drug delivery pen that is coupled to a treatment element. The treatment element improves the pharmacokinetic and/or pharmacodynamic properties of the drug that is being delivered to the target tissue using a fluid jet. The drug delivery injector for administering a drug, for example, insulin, as a jet nozzle configured for firing insulin in a fluid jet in a configuration and with sufficient velocity to penetrate tissue of the patient to a delivery site. A drug containing compartment is associated with the nozzle for containing the drug and feeding the insulin to the delivery nozzle for injection. A firing mechanism includes an energy source is associated with the drug compartment for forcing the drug through the nozzle at a sufficient velocity to penetrate to the target site. In some embodiments, the energy source producing the fluid jet can be a coil spring, gas spring, or any other spring. A trigger or a dosage release button of the drug delivery injector is movable by the user and associated with the firing mechanism for activating the energy source that produces the drug fluid jet by forcing of the drug through the nozzle once the release button is activated.
- In some embodiments, the applied treatment induces vasodilatation through neural stimulation of the tissue of the drug injection site. The neural stimulation can be induced by thermal stimulation and/or mechanical stimulation and/or chemical stimulation. The human neural response to the thermal stimulation includes several mechanisms such as the Nociceptive Axon Reflex that induce vasodilatation among other effects.
- In some embodiments, the induced neural response, such as the Nociceptive Axon Reflex, also induces widening of the capillary pores and increasing the capillary wall permeability. This effect is also significant for improving the absorption of the drag through the capillary wall.
- In some embodiments, the applied treatment may lead to a reduction in the variability of the drug absorption in the blood or lymph system and its local and systemic effects. For example, heating the tissue region in the vicinity of the area of drug delivery to a preset regulated temperature during and/or after the drug injection and absorption into the blood may cause local blood perfusion at that region to become more reproducible and the drug absorption process more uniform and reproducible as well. Also, by reducing the delay between drug injection into the tissue and absorption into the blood system, the variability of drug action induced by the delayed profile can be reduced. In some embodiments, the temperature of the region adjacent to the injection region can be regulated for longer periods, but the cost may be the energy source volume and weight. Therefore, for minimization of the energy source size, the heating period or heating temporal profile can be optimized in relation to the period of the drug injection and absorption into the blood. In some embodiments, in which the treatment utilized is, for example, heat, the drug interaction with the treatment substance or type will be taken into consideration and can be avoided. For example, a drug's temperature sensitivity will be accounted for so as to avoid protein denaturisation. Insulin is a temperature-sensitive protein and to avoid damage to the insulin the treatment protocol, heating can be limited to ensure the efficacy of the delivered drug. For example, the treatment protocol may control the temperature or the location of the treatment delivery site so as to not damage the drug.
- In some embodiments, the neural response that induces vasodilatation is stimulated by applying a mechanical force in the vicinity of the drug infused region, wherein the force includes, but is not limited to, one or more of the following: pressure, massage, vibration, suction and/or any other mechanical stimulation. These tissue treatments or stimulations are known to stimulate the Nociceptive Axon Reflex as well. Among the advantages of the mechanical stimulation is the fact that it does not damage the drug, whereas for example heating insulin above 37° C. may cause damage to it. The calibration of the applied mechanical force may be performed by using one of the procedures discussed above.
- In some embodiments, an additional fluid substance can be combined with the drug or, alternatively, injected, infused, or topically applied (which may include transdermal delivery of the drug by permeating through the skin of the patient) to the drug injection site, such that the additional substance induces neural stimulation that leads to local vasodilatation and/or increases of the capillary permeability. The substances can include tolazine, naftidrofuryl, suloctidil, nitroprusside, capsaicin, or any other suitable substance. In some embodiments, an additional substance may induce vasodilatation and improve blood perfusion in the drug infused tissue region. For example, capsaicin stimulates a neural response through the VR1 receptor and produces a similar response to thermal neural stimulation.
- The treatment element can be an integral part of the drug delivery injection pen, according to some embodiments of the present invention. In some embodiments, the treatment element can be an auxiliary unit that may be interchanged, replaced, or added to an existing drug delivery injection pen. Such a device can be attached to the drug delivery pen either during or before the drug injection or applied to the drug injection site afterward.
- The treatment element, according to some embodiments, may be any one or more of (or a combination of): a heating element, a radiation emitter, a sound transducer, a mechanical/electo-mechanical vibration device, a light emitting device, and an electrode.
- In some embodiments, one or more of properties relating to the treatment element may be controlled by a processor in order to achieve a desired response of the tissue region undergoing drug delivery. Such properties include amplitude, phase, frequency, combination of excitation sources, relative ratio and timing between various excitation sources, or any other properties. In some embodiments, the treatment type or sources can be also adjusted according to chemical and/or physical properties of the drug being delivered. The tissue response to the treatment element/stimulation enhances the functionality of the injected drug by enhancing the kinetics of molecular transport from the injection site inside the tissue to various compartments surrounding the tissue region and to the blood system.
- In some embodiments, a treatment element or device supplying tissue treatment or stimulation to a tissue region can be configured to monitor and control properties of the treatment source. For example, controllable properties of a treatment protocol include amplitude, phase, intensity, frequency, or any other properties. Further control can be gained by actively monitoring, such that the information is provided to a controller (“controller” or “processing unit”) that uses the information to reduce the variability of the drug pharmacokinetics. In such embodiments, the device can be configured to monitor properties of the adjacent tissue, such as local blood perfusion or skin temperature. Based on such monitoring, the information can be provided to the controller that utilizes the information to improve pharmacokinetic or pharmacodynamic profile of the drug as well as its performance and reduce variability of the drug injection process.
- In some embodiments, the present invention's device includes a sensor or other triggering input mechanism that is configured to prevent deployment of the drug delivery pen unless certain criteria are fulfilled. Such criteria can include activation of a treatment protocol or element.
- In some embodiments, tissue treatment can be applied simultaneously with each injection of the drug delivery. In other embodiments, the tissue treatment or stimulation option may be selected manually by the user. In some embodiments, the user may choose to attach the treatment element to the drug delivery pen. The user can enable or disable mechanically the automatic application of treatment element. The user can activate the treatment device or devices before or after the drug injection to enhance the tissue response to the injected drug. Such activation can be done by pressing a button or a sequence of buttons on the drug delivery pen.
- For example, in case of an insulin delivery pen, the pen may have a special button for triggering a “fast bolus” as compared to regular bolus injection provided by the drug delivery injection pen. The fast insulin bolus mode can be configured to start one of the above treatments parallel to the injection of insulin or short time before or after the injection of the insulin bolus for a given period of time. This improves or modifies pharmacokinetics or pharmacodynamics of insulin administration, tissue blood perfusion and/or absorption in the blood of a patient and is highly advantageous when applied in conjunction with high glycemic index foods. Application of a “fast bolus” may be useful for consumption of high glycemic index foods, where larger rapid glucose excursions occurs, but also in most of the cases of using insulin boluses for prandial coverage. In some embodiments, application of a “fast bolus” can be set as the default mode of the drug delivery pen. In some embodiments, the user may apply the tissue treatment or stimulation before the meal to further increase the treatment effect.
- In some embodiments, at least one effect of the treatments is to reduce local irritation caused by the infused drug or local inflammation reaction caused by the injection. For example, in case of insulin injection, reducing the period in which the high concentration of insulin remains in the tissue may reduce irritation that may be caused by insulin. It can also reduce unwanted effects of the insulin delivery, such as, lipohypertrophy.
- Some embodiments of the present invention also provide methods for improving or modifying a drug's pharmacokinetic or pharmacodynamic profile in order to reduce time to peak action in the blood of the injected material by applying a modulation pattern to the infused drug. With this modulation, the injection drug fluid is slightly moved/pulled in and out of the tissue during or after the drug injection process. In such embodiments, this method may not require an additional device applied to the skin.
- In some embodiments, the drug delivery pen can mechanically attach a small disposable device to the skin either before, during or after delivery of the drug. The disposable device can apply a treatment or treatments using at least one of the following sources: a heat source (such as a heat resistor), a suction port, for example activated by a pump, a mechanical vibration source, an ultrasound excitation source, an ultrasound transducer, a light source, a massaging element, electromagnetic radiation source, electric field source, magnetic field source, additional substance and/or a combination of at least two of sources to improve drug pharmacokinetics. In some embodiments, the small disposable device can be attached manually either before or after injection of the drug.
- In some embodiments, a device for drug injection includes a disposable injection needle for injecting drug into tissue, a reusable drug delivery pen for inserting the needle into the patient skin or subcutaneous layer and for injection of the drug through the needle into one of the skin and/or subcutaneous tissue layer, a treatment device for applying a specific treatment or stimulation to the drug injected region in order to improve drug's pharmacokinetic, pharmacodynamic profile and/or to increase blood perfusion in that region before, during and/or after the drug injection period to improve drug absorption into the blood system. The needle can be injected automatically at the target site using an automatic needle triggering piston or spring. In some embodiments, the needle can be injected at the target site manually through the action of the user inserting the needle independently.
- In some embodiments, a device for drug injection includes an injection catheter for insertion into the tissue, a drug injection device for infusing a drug into the injection catheter, a treatment device for applying a specific treatment or stimulation to the drug infused region in order to improve, modify and/or stabilize the drug pharmacokinetics, pharmacodynamics, and/or to reduce variations of the drug absorption into the blood system.
- In some embodiments, a device for drug injection includes at least one of the following: a display, a button, a memory for boluses, a processing unit, a sensor for skin properties, a sensor for treatment level, a glucose sensor, a user interface, wireless connection to a PDA or cell phone for having memory and reminders and remote access to support sites.
- In some embodiments, the device for drug/insulin injection includes a glucose sensor. The glucose sensor may measure blood glucose level at alternate sites (for example, at sites with reduced blood perfusion, such as arms and legs). The glucose sensor can be provided on the opposite side the injection end.
- In some embodiments, the present invention can be configured for a jet injection. Jet injection involves high pressure injection of material, which obviates the use of needles. This type of injection mode is also referred to as “needle free” or “needleless” injection. In some embodiments, the pen injection device can include a jet injection, in addition to or in place of, the use of one or more needles. Some examples of conventional needle-free injection systems include the Medi-Jector VISION® and some products by Antares. Such systems can be adapted for use with the present invention's jet injection system.
- In some embodiments, the injection device includes a disposable nozzle and a reservoir having an additional substance. The reservoir is located at the nozzle and the additional substance is provided in a single use or single dose amount. The reservoir is located within the body of the device and the nozzle features a connector for fluid or other communication with the reservoir.
- In some embodiments, rather than disposing a nozzle along with an additional reservoir, an applicator for an additional substance is provided that is attached to or separate from the device. The nozzle can be disposed along with a gauge for adjusting the amount of additional substance to be applied. The applicator may be controlled through a button or other control component. In some embodiments, the gauge can be configured as a ring that can be rotated around the applicator button or other control device to adjust the amount that the button is pressed and/or some function of the other control device and/or to adjust the dose of applied additional substance.
- In some embodiments, the drug delivery pen can include an adhesive material, such as a sticker, for assisting the user to create a skin fold for administration of the drug and/or additional substance.
- The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in order to provide what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
-
FIGS. 1A-E illustrate an exemplary drug delivery pen combined with a mechanism for topical application of an additional substance to the drug injection site, according to some embodiments of the present invention. -
FIGS. 2A-C illustrates an exemplary drug delivery pen combined with a mechanism for topical application of an additional substance to the drug injection site, according to some embodiments of the present invention. -
FIGS. 3A-C illustrates an exemplary drug delivery pen combined with a mechanism for topical application of an additional substance to the drug injection site, according to some embodiments of the present invention. -
FIGS. 4A-D illustrates an exemplary drug delivery pen combined with a mechanism for topical application of an additional substance to the drug injection site, according to some embodiments of the present invention. -
FIGS. 5A-C illustrates an exemplary drug delivery pen combined with a mechanism for application of a treatment element on the drug injection site, according to some embodiments of the present invention. -
FIGS. 6A-C illustrates an exemplary drug delivery pen combined with a mechanism for application of a treatment element on the drug injection site, according to some embodiments of the present invention. -
FIGS. 7A-C illustrates an exemplary drug delivery pen and cover combined with a mechanism for application of a treatment element on the drug injection site, according to some embodiments of the present invention. -
FIGS. 8A-D illustrates an exemplary drug delivery pen combined with a mechanism for application of a treatment element on the drug injection site, according to some embodiments of the present invention. -
FIGS. 9A-C illustrates an exemplary drug delivery pen combined with a mechanism for application of a treatment element on the drug injection site, according to some embodiments of the present invention. -
FIGS. 10A-F illustrates an exemplary treatment element that may be coupled to a drug injection at the drug injection site, according to some embodiments of the present invention. -
FIGS. 11A-E are block diagrams of exemplary drug delivery devices, according to some embodiments of the present invention. -
FIGS. 12A-C illustrate an exemplary drug delivery pen combined with a mechanism for application of a treatment element on the drug injection site, according to some embodiments of the present invention. -
FIG. 13 is a flow chart illustrating an exemplary method for controlling temperature of heating that is provided by a treatment element in order to prevent degradation of a temperature sensitive drug. - The present invention relates to a drug delivery pen or other drug injection devices for the injection of a drug at a drug injection site, where the drug in injection device applies a treatment that can improve injected drug's pharmacokinetic and/or pharmacodynamic properties. The following description will refer to a drug injection pen for illustrative, non-limiting purposes, however, as can be understood by one skilled in the art, the present invention is applicable to any other drug injection devices.
-
FIGS. 1A-C are schematic diagrams of an exemplarydrug delivery pen 100 having a treatment element coupled to the delivery pen, according to some embodiments of the present invention.FIGS. 1A and 1B depict an exemplarydrug delivery pen 100 having apen shaft 110, an injection piston release trigger/button 112 (for actuating a piston pump, for example, within the housing of the delivery pen), a treatment release trigger/button 108 (for actuating a pump for delivering the treatment), a needle opening and ahousing 102,treatment delivery openings 104, and adrug dosage selector 106.FIG. 1A is a perspective view of thedrug delivery pen 100.FIG. 1B is a side view of thepen 100. - The drug delivery pen, for the delivery of insulin, may function as do state of the art drug delivery pens by injecting the selected and
determined drug dosage 106 and using injectionpiston release button 112 to release the piston (not shown) that presses and/or otherwise places pressure on the drug reservoir syringe or vial, for causing injection of the required dosage of drug (not shown) into the targeted area and throughneedle housing 102. In some embodiments, a fluid jet of the delivered drug can be utilized instead of a syringe to delivery the drug throughhousing 102 to the targeted delivery site. The drug delivery pen can provide an additional treatment element, such as, an anesthetic, a drug for inducing treatment, a drug for improving effectiveness of the primary drug being injected. The primary drug can be insulin. - The treatment can be delivered over the target tissue using the
treatment delivery openings 104, wherein a fluid treatment substance can be applied or sprayed onto the tissue.FIG. 1C is a cross-sectional view of thedrug delivery pen 100 showing thetreatment element 130 and components thereof.Treatment element 130 includestreatment compartment 120, a plurality ofvalves 122, apump 126 and atreatment release button 128. In some embodiments, thetreatment compartment 120 stores a formulation of a liquid, ointment, solution, aerosol, foam, solid, gel foam, pressurized liquid, gas, spray, pain reliever drug, analgesic, vasodilatation drug, septic, alcohol, or the like for treatment of the skin tissue area. In some embodiments, treatment may be applied prior to or following deployment of the needle. - Treatment substance stored in
compartment 120 can be pumped to thetreatment release openings 104 usingschematic pump 126 that is activated by pressingtreatment release button 128. Thetreatment release button 128releases valves 122 to deliver treatment liquid from thecompartment 120 through thetube 124 that leads toopenings 104. The treatment applied to an area can lead to improved pharmacokinetic and/or pharmacodynamic properties of the primary drug being delivered by way of injection. The pathway by which the pharmacodynamic and/or pharmacokinetic properties of the drug are improved may be dependent on the treatment substance or element utilized. -
FIG. 1D is a partial exploded view of adrug delivery pen 140 having amanual injection portion 141, according to some embodiments of the present invention.Pen 140 includes apen body 150, adosage release button 142, atreatment release button 148, adrug dosage selector 146, and aninjection coupling portion 144.Injection coupling portion 144 is a connection mode to securely affixinjection portion 141 to thepen portion 140. The coupling of theinjection portion 141 to thepen portion 140 may be accomplished by at least one or more connecting pieces, such as, male/female connectors, threaded connectors, snap connector(s), turn key connectors, hook connectors or any other suitable connectors. -
Manual injection portion 141 includes atreatment substance reservoir 152, atreatment delivery opening 154 and aneedle 158. Themanual injection portion 141 can be disposable after a single use. However, theinjection portion 141 can be reusable and can be used a number of times or repeatedly over a period of time. Prior to drug delivery the drugdelivery pen body 150 is securely coupled tomanual injection portion 141 allowing a user to use thedrug delivery pen 140 by selecting a drug dosage usingdosage selector 146.Treatment release button 148 triggers the release of the treatment substance from thetreatment reservoir 152 throughdelivery openings 154. The timing of treatment release can be performed prior to, during or following drug delivery, or in a combination thereof. Drug delivery can be accomplished by setting the dosage amount usingdosage selector 146, manually insertingneedle 158 into the target site, releasing treatment substance throughdelivery openings 154 and finally delivering the drug withdosage release button 142. -
FIG. 1E depicts an additional optional embodiment of the manual drug delivery pen ofFIG. 1D . Manual drug delivery pen includes a drugdelivery pen housing 160 andmanual injection portion 161.Pen housing 160 includes apen body 170, adosage release button 162, adrug dosage selector 166, atreatment release button 168, atreatment dosage selector 178, atreatment substance tube 176, and aninjection coupling portion 164. Theinjection coupling portion 164 can be configured to securely affixinjection portion 161 to thepen body portion 160. Coupling of theinjection portion 161 topen portion 160 can be accomplished by at least one or more connecting pieces, such as, a male to female connector(s), threaded connectors, snap connector(s), turn key connector(s), hook connectors or any other connection devices. -
Manual injection portion 161 is disposable for single use, however,injection portion 161 may be used a number of times, or repeatedly over a continuous period of time. Prior to drug delivery the drugdelivery pen body 170 is securely coupled tomanual injection portion 161 allowing a user to usedrug delivery pen 160 by selecting a drug dosage usingdrug dosage selector 166.Treatment dosage selector 178 determines the dosage of the treatment substance to be released withtreatment release button 168. Pressingtreatment release button 168 triggers the release of the treatment substance from the treatment reservoir (not shown) through at least one or moretreatment delivery tube 176 that ends intreatment delivery openings 174. Timing of treatment dosage selection and release may be performed prior to, during or following drug delivery, or in a combination thereof. Drug delivery is accomplished by setting the dosage amount usingdosage selector 166, manually insertingneedle 158 into the target site, releasing treatment substance throughdelivery openings 174 as described above and finally delivering the drug withdosage release button 162. -
FIGS. 2A-C illustrate an exemplary drug delivery pen according to the present invention which is similar to the embodiments depicted inFIGS. 1A-C . InFIGS. 2A-C embodiments, the treatment opening is on the opposite side of the needle housing.FIGS. 2A and 2B depict adrug delivery pen 200 including apen shaft 210, aninjection release button 208, atreatment release button 212, a needle opening and ahousing 202, atreatment delivery opening 204 and adrug dosage selector 206.FIG. 2A is a perspective view of thedrug delivery pen 200.FIG. 2B is a side view ofpen 200. - The drug delivery, such as insulin delivery, functions in a similar fashion as some conventional pens, such as NovoPen, FlexPen, Sanofi Aventis pens or the like, by setting the
determined drug dosage 206 and pressing an upper button (not shown inFIGS. 2A-C ) that pushes the syringe piston (not shown inFIGS. 2A-C ) at the required distance to inject the dosage that was set, such thatinjection release button 208 is not required. For other pens, such as the Autopen 24, after setting thedetermined drug dosage 206, the drug is injected by releasing theinjection release button 208 which releases the piston (not shown inFIGS. 2A-C ) that pushes the syringe piston to the required distance to inject the desired dosage as set bydial 206. In some pens, for drug delivery, the drug is accomplished by setting thedetermined drug dosage 206 and pressing theneedle release button 208, to release the needle (not shown inFIGS. 2A-C ) into the targeted area and throughneedle housing 202, thereby injecting the required drug dosage through that needle. However, the drug delivery pen according to the present invention provides an additional treatment element, such as, in the form of another drug, to induce a treatment for improving the primary drug being injected. The above injection pen's configuration and mechanism as well as other injection devices, such as syringes or jet injectors, can be configured to be used with devices and methods for applying additional treatment to the vicinity of the drug injection site, as described by the present and related applications. In some embodiments, the primary drug can be insulin. - The treatment is delivered over the target tissue using the pen's
treatment delivery openings 204, wherein a fluid treatment substance is applied onto the tissue.FIG. 2C is a cross-sectional view ofdrug delivery pen 200 showing thetreatment element 230 and components thereof.Treatment element 230 includes atreatment compartment 220, a plurality ofvalves 222, apump 226, atreatment tube 224 and atreatment release button 228. Thetreatment compartment 220 stores a formulation, a fluid, such as a liquid, ointment, solution, aerosol, pressurized liquid, gas, spray, pain relieve drug, analgesic, vasodilatation drug, septic, alcohol, or the like for treating the skin tissue area. The treatment may be applied prior to or following deployment of the needle, in a two step process one end of the pen for substance treatmentdelivery using opening 204 and the opposite end for theinjection using housing 202. - A treatment substance stored in the
compartment 220 can be pumped to thetreatment release openings 204 usingschematic pump 226 that is activated by pressing thetreatment release button 228. Thetreatment release button 228releases valves 222 to deliver treatment liquid from thecompartment 220 through thetube 224 that leads to theopenings 204. In some embodiments, the treatment applied to an area may lead to improved pharmacokinetic and/or pharmacodynamic properties of the primary drug being delivered by way of an injection. The pathway by which the pharmacodynamic and/or pharmacokinetic properties of the drug are improved may be dependent on the treatment substance or element utilized. -
FIGS. 3A-C illustrate an exemplary pen-type drug delivery device similar to that described in connection withFIGS. 1A-E and 2A-C, however, in this case, the treatment substance is applied by way of a roller-applicator ball 304 onto the tissue being treated.FIGS. 3A and 3B illustrate similar views of drug delivery pen 300. The drug delivery function of pen 300 is similar to the functions of pens shown inFIGS. 1A-E and 2A-C. The drug dosage can be controlled and determined using adosage dial 306 that is delivered via theneedle housing 302 that encloses a needle (not shown inFIGS. 3A-C ), which is triggered using aninjection release button 312. A treatment substance may be applied to the injected area either prior to or following injection. -
FIG. 3C depictstreatment element 330 includingtreatment substance container 320 andsubstance application ball 304. Thetreatment compartment 320 stores a fluid, such as, a liquid, ointment, solution, aerosol, pressurized liquid, gas, spray, pain relieve drug, analgesic, vasodilatation drug, septic, alcohol, or the like for treating the skin tissue area. Treatment may be applied with aball 304 prior to or following deployment of the needle, in at least a two-step process one end of the pen for substance treatmentdelivery using ball 304 the opposite end for theinjection using housing 302. -
FIGS. 4A-C illustrate another exemplarydrug delivery pen 400, according to some embodiments of the present invention.Treatment substance 430 used to improve the pharmacokinetic and/or pharmacodynamic properties of the drug being delivered, such as insulin, may come in the form of a solid, gel, gel form, thixotropic solution or the like. Thesubstance 430 may be applied to a treatment area either prior to or following drug delivery using a needle delivered throughneedle housing 402. Thetreatment substance 430 can be a solid, stick, ointment, solution, pain relieving drug, analgesic, vasodilatation drug, septic, alcohol, or the like to treat the skin or tissue area.Substance treatment 430 can be rubbed, rolled over the treated area or applied in any other suitable way. - The
drug delivery pen 400 may be manufactured separately from theindividual treatment substance 430; alternative, thedrug delivery pen 400 may be manufactured along withtreatment substance 430 being coupled thereto.FIG. 4D depicts thetreatment substance 430 that can be configured to fit over thepen shaft 410 using a sticker, a threading, an adhesive layer, a clip, or any other coupling tools. Thepen shaft 410 can be pushed through the lumen oftreatment substance 430. Thetreatment substance 430 can be configured to fit circumferentially around thepen shaft 410. In some embodiments, a single use or areusable treatment substance 430 can be used with other drug injection devices, such as a syringe. -
FIG. 5A illustrates an exemplary drug delivery injectable pen having a needle housing that can accept secondary devices for substance treatment deployment or use, according to some embodiments of the present invention.Drug delivery pen 500 includesshaft 510 that is configured to contain a volume of the injectable drug (such as insulin) for delivery. Adosage dial 506 sets the dosage to be injected with a needle that is injected via aninjection release button 520 through the needle and theneedle housing 502. - In some embodiments, the
drug delivery pen 500 includes aglucose sensor 501 for measuring blood glucose with a finger stick.Glucose sensor 501 can be configured to be on the top of thedrug delivery pen 500. Thepen 500 can be used to release a needle that is used to draw a drop of blood that may be placed over a finger stick (not shown inFIGS. 5A-C ) and is placed over theglucose sensor 501 for reading the glucose levels in the drawn blood sample. Additionally, the drop of blood can be applied to a finger stick like glucose sensor inserted into a glucometer type slit, for example on the top of pen 500 (not shown inFIGS. 5A-C ). -
FIG. 5B depicts atreatment element apparatus 530 that may be coupled to thedrug delivery pen 500, as shown inFIG. 5C , to formdrug delivery apparatus 540. Thedrug delivery apparatus 540 including thetreatment element apparatus 530 anddrug delivery pen 510 may be single unit. - The
treatment element apparatus 530 includes afemale connector 524 that can be securely coupled to theneedle housing 502, which has a corresponding male connector shape. The coupling can be undertaken by threading, fitting, pin lock assembly, adhesives or any other coupling methods. Thedrug delivery pen 530 includestreatment substance dispenser 520 that contains aroll 520 adhered to a plurality oftreatment element 526. Thetreatment element 526 can be securely placed over the end ofneedle housing 502. Thetreatment element 526 can be implemented in the form of a pad (e.g., releasing an additional substance), a heating pad, a PCB heating element, an optical treatment element, an electromagnetic radiation treatment element, an electrical current treatment element, an acoustical treatment element, a massaging treatment element or an element related to any of the treatment methods discussed above. Thetreatment element 526 can deliver treatment to a target tissue prior to injection, following injection, or at the time of injection to improve the pharmacodynamic and/or pharmacokinetic properties of an injectable drug.Treatment element 526 can also include a power source to provide the desired treatment power. Treatment element can include a control element, such as an electrical circuit, to control the treatment profile. Treatment element can be disposable, e.g., single use treatment element, whereby after the treatment profile ends, the user can dispose of thetreatment element 526. Treatment element can be reusable, whereby after the treatment profile ends, the user can recharge it, exchange the power source, or exchange only a portion of thetreatment element 526 that is disposable and then reload it into a new or the sametreatment substance dispenser 520 or asubstance dispenser 630 shown inFIG. 6A or any other configuration, as disclosed in the present application. -
FIGS. 6A-C illustrate exemplary treatment element dispensers that may be coupled to adrug delivery pen 500, as illustrated inFIG. 5A .FIG. 6A illustrates atreatment dispenser 630 that is an optional alternative todispenser 530 ofFIG. 5B .Treatment dispenser 630 includesstackable treatment elements 626 that may be coupled to the pen drug delivery device.FIG. 6B illustrates how a drug delivery pen is coupled to thetreatment element dispenser 630. Once thetreatment element dispenser 630 is decoupled from thedelivery pen apparatus 650, the needle end of the apparatus is coupled with atreatment element 626. Thetreatment element 626 is alignable with the needle ofdrug delivery pen 650. This alignment provides for a drug delivery andtreatment apparatus 650 to induce application oftreatment using element 626 prior to, following, or at the same time as undertaking drug delivery with the drug delivery pen 600 in a one step process. - In some embodiments, the drug delivery using the pen 600 and evoking
treatment using element 626 may be undertaken in a two-step process, wheretreatment element 626 is coupled to a non-needle end of the drug delivery pen 600. This allows drug delivery and treatment to be performed individually. For example, one can trigger the drug delivery with the injection release button 612 and later evoketreatment using element 626. The reverse is also true where treatment may precede drug delivery. - In some embodiments, the treatment element, such as treatment element 526 (shown in
FIGS. 5A-C ) orelement 626, is coupled to a single use needle that is secured to the pen before each dose injection (as shown inFIGS. 1D and 1E ), such that when the needle is inserted into the body, the treatment element is attached to and/or otherwise adheres to or around the injection site, automatically, without the need of additional operations by the user. - For any of the embodiments shown herein, the treatment element may include an energy source, which can provide heat, radiation, mechanical vibrations, suction, magnetic energy, ultrasound, light irradiation, RF irradiation, microwave irradiation, electrical stimulation, or any other form of energy or combinations of those energy sources. For example, the treatment element may include a heater to heat the injection site; or a source of optical energy for the energy source, such as a light source, including but not limited to LEDs or laser diodes for example, with one or more other optical elements; or a micro-wave generator or emitter configured to irradiate the injected region with micro-wave radiation; or a radio frequency electromagnetic radiation generator or emitter configured to irradiate the injected region with radio frequency electromagnetic radiation; or a vibration device configured to vibrate the injected region; or a vacuum device for applying suction to the injected region; or an electric field generator or emitter configured to apply an electric field to the injected region; or a magnetic field generator or emitter configured to apply magnetic field to the injected region; or an acoustic signal generator or emitter configured to apply acoustic stimulation to the injected region.
-
FIGS. 7A-C illustrates an exemplarydrug delivery pen 700 similar to the pens shown inFIGS. 5A-C and 6A-C, that is coupled to atreatment element dispenser 730 as shown inFIG. 7B to create drug delivery andtreatment apparatus 750. Theapparatus 750 includes atreatment element dispenser 730 at the non needle end ofdrug delivery pen 700. Theapparatus 750 provides the drug delivery pen with an ability to deliver drug(s) in a chosen dosage while providing the treatment element that may improve the pharmacokinetic and/or pharmacodynamic property of the delivered drug. In some embodiments, the user can store his/her treatment element(s) in a special case, or in the case of the drug injection device. Before or after the drug injection, the user inserts the treatment element, as discussed above, into thetreatment element dispenser 730 and applies it to the injection site. In some embodiments, the treatment element can have a similar shape as thetreatment element dispenser 730 and can be coupled directly to thedrug delivery pen 700 without using the treatment element dispenser as an adaptor. -
FIGS. 8A-D illustrate an exemplary treatment apparatus, similar to the one shown inFIGS. 1A-3C , according some embodiments of the present invention.FIG. 8A depicts adrug delivery pen 800 used to deliver an injectable drug.FIGS. 8B and 8C are views of thetreatment element 830 that can be coupled to thedrug delivery pen 800, thus, forming a drug delivery and treatment apparatus, as shown inFIG. 8A . Thetreatment element 830 can be coupled to thepen 800 via theopening 840 that receives the needle end of thedrug delivery pen 800.Treatment element 830 includes atreatment substance compartment 820 that can be utilized to store treatment fluid. Thetreatment compartment 820 stores a fluid, such as gel, foam, liquid, ointment, solution, aerosol, pressurized liquid, gas, spray, pain relieve drug, analgesic, vasodilatation drug, septic, alcohol, or the like for treating the skin tissue area. Treatment can be applied prior to or following deployment of the needle. - Treatment liquid stored in the
compartment 820 can be delivered to the target tissue through theopening 804 usingpump 826 that is activated by pressing thetreatment release button 828. Thetreatment release button 828releases valves 822 to deliver treatment liquid from thecompartment 820 through thetube 824 that leads to theopening 804. In some embodiments, the amount of treatment liquid can be preset for a user. In some embodiments, a special dial or other means, (not shown inFIGS. 8A-D , but illustrated inFIG. 1E ), may be used to set the amount of applied treatment substance. The treatment applied to an area can lead to improved pharmacokinetic and/or pharmacodynamic properties of the primary drug being delivered by way of injection (e.g., insulin). The pathway by which the pharmacodynamic and/or pharmacokinetic properties of the drug are improved is optional and may be dependent on the treatment substance or clement utilized. -
FIGS. 9A-C illustrate thedrug delivery pen 900 having the treatment element provide pressure-related treatment, such as suction, massage, or the like, according to some embodiments of the present invention.FIG. 9A depicts a drug delivery pen andtreatment apparatus 950 including adrug delivery pen 900 and atreatment element attachment 930 that can be mechanically coupled. Theapparatus 950 can be provided as an assembled or unitary drug delivery device. Theapparatus 950 can be coupled to thetreatment element 940 that is made from a pliable material that can withstand pressure. Such material can be rubber, latex, or any other suitable material configured to create suction over a given treatment area similar to a plunger. Theapparatus 950 is placed over thetreatment element 940 and is compressed to create further pressure, as shown inFIGS. 9B and 9C , or suction when the pen is lifted. Such suction will bring about vasodilatation in the treated tissue and is configured to improve pharmacodynamics and/or pharmacokinetics of the delivered drug. Drug delivery deployment can be undertaken in the compressed form of thetreatment element 940, as shown inFIG. 9C . -
FIGS. 10A-D illustrate a variety of pressure based treatment elements, according to some embodiments of the present invention.FIG. 10A is a cross-sectional view of the treatment element shown inFIG. 10B . The treatment element can be used during drug delivery and includes alumen 1000 allowing the needle to penetrate through.FIG. 10C is a cross-sectional view of the treatment element shown inFIG. 10D . The treatment element ofFIG. 10D can be utilized either prior to or following drug delivery in order to create suction over the tissue area. The treatment elements ofFIGS. 10A-D can be used to create suction or vacuum in the vicinity of the drug injection site and to induce local vasodilatation. -
FIGS. 10E and 10F illustrate an exemplary treatment element configured as a durable adhesive tape that is used to effectively pinch a fold of skin while maintaining its shape. The treatment element shown inFIG. 10E includes twosticky ends 1050 that are bridged by amalleable section 1052. Each one of theends 1050 is placed over a patch of skin where an injection for example with a syringe or a drug delivery pen is to be undertaken. Once in place, theends 1050 are pushed toward each other by themalleable section 1052 to form a bell type shape.Section 1052 can be manufactured from a strong malleable material that can hold its shape, while being repeatedly formed and deformed.FIG. 10F depicts the treatment element ofFIG. 10E in a folded form.Section 1052 can be moulded and reshaped forming a treatment element for example to bring about vasodilatation. -
FIG. 11A is a block diagram of an exemplarydrug delivery apparatus 1100 having atreatment element 1102 incorporated into adrug delivery pen 1104, wherein the treatment element is integrated into the drug delivery pen, according to some embodiments of the present invention.FIG. 11B is a block diagram of an exemplarydrug delivery apparatus 1110 having atreatment element 1112 and adrug delivery device 1114 that are removably coupled to each other, according to some embodiments of the present invention. Thedrug delivery device 1114 ortreatment element 1112 can function independently of one another and can be securely coupled to each other to form a single drug delivery andtreatment apparatus 1110, similar to the embodiment ofFIGS. 4A-6C .Drug delivery device 1114 can be implemented as a syringe, drug delivery pen, drug delivery jet injector or the like. -
FIG. 11C is a block diagram of an exemplary drug delivery and treatment apparatus that further includes asensor 1126, such as a glucose stick sensor, for measuring blood glucose. Thedrug delivery apparatus 1120 communicates with anexternal processing unit 1130. The processing unit can be a PDA, a cellular phone, a computer, a laptop or any other device. Theunit 1130 includes acontroller 1132 and adisplay 1134. Thecontroller 1132 controls analysis of data received from thedrug delivery apparatus 1120 to determine treatment or dosage form or the like related to the functioning ofdrug delivery pen 1124, andtreatment element 1122. Theprocessing unit 1130 provides the user with data regarding historical and current use of thedrug delivery apparatus 1120. -
FIG. 11D is a block diagram of an exemplary drug delivery device similar to the device shown inFIG. 11C , where thedrug delivery apparatus 1140 has an integratedsensor 1146, aprocessing unit 1150 and adisplay 1148, according to some embodiments of the present invention. This allows the user to fully control, visualize all activity related to thedrug delivery pen 1144 or thetreatment element 1142. -
FIGS. 12A-C schematically illustrate exemplary treatment element dispensers that may be coupled to a drug injection device 1200 (as shown inFIG. 12C ), according to some embodiments of the present invention.FIG. 12A illustrates atreatment element 1210 with apower source 1211. In some embodiments, thetreatment element 1210 includes a power source and a control element to control a treatment profile. For instance, in case of heating,treatment element 1210 can include a heater to heat the tissue around the injection site to a temperature that improves drug's pharmacokinetics and pharmacodynamics. In case of temperature sensitive drugs, such as insulin,treatment element 1210 can include a heater to heat the tissue around the injection site to a temperature that improves drug's pharmacokinetics and pharmacodynamics, without heating the drug above a limiting temperature that may degrade it, such as 37° C. in the case of some types of insulin.Treatment element 1210 may include also an adhesive layer on its bottom side covered with alaminate 1212. - In some embodiments the user has a case with one or
few treatment elements 1210. When the user wants to use treatment element over drug injection site, the user takesadaptor 1220, which can be stored in the same case or a different one, and attaches onetreatment clement 1210 toadaptor 1220, as shown inFIG. 12B .Treatment element 1210 can be attached toadaptor 1220 with a weak mechanical locking, such as a plastic clip, or weak adhesive or other ways known in the art. Then laminate 1212 can be removed. Afterwards,adaptor 1220 is assembled or threaded over drug delivery pen orsyringe 1230, as shown atFIG. 12C . In some embodiments needle cap 1231, can be removed from the needle. Then, the needle is inserted into injection site tissue, the drug injection device is operated and the drug is injected through needle into the tissue. During that time, or slightly before or afteradaptor 1230, is pushed down to the tissue andtreatment element 1210 is attached to the tissue around drug injection site. - In some embodiments, the attachment of
treatment element 1210 to the tissue is configured to activate it automatically and the treatment starts according to a predetermined treatment profile. This function can be performed, for example, by a small switch which is pressed whentreatment element 1210 is attached to the tissue. In some embodiments, thetreatment element 1210 can be activated manually. In some embodiments, treatment element can be controlled and/or programmed for a specific treatment element through a remote control or a connection to its case. Afterwards, theinjection device 1230 and theadaptor 1220 are lifted off, either together or separately, and thetreatment element 1210 is left attached to the tissue and applies treatment to the vicinity of the drug injection site. The user can remove treatment element after treatment ends or later on. In some embodiments, the treatment element includes an indicator for the user that indicates the beginning of the treatment and the end of the treatment. In some embodiments, thetreatment element 1210 may be disposable. - In some embodiments, the treatment element's 1210
power source 1211 may be rechargeable, so that after the treatment ends and the user removes it from the skin, it can be put back to the case and/or placed in a charging cradle for recharging which may be disposed in said case. In some embodiments, thetreatment element 1210 may have a disposable portion and a reusable portion. In some embodiments, the drug injection device and at least one treatment element are disposed in the same case prior to injection. This provides additional comfort for the user and allows the user to use both of them together or one after the other. -
FIG. 13 is a flow chart depicting a method for controlling the temperature of heating provided by a treatment elements that heat the injection site tissue vicinity in order to prevent degradation of a temperature sensitive drug. As shown instep 1300, a drug is provided for injection to the patient, where the drug is sensitive to degradation above a limiting temperature. Instep 1301, a treatment element is provided that features a controllable heating through a controllable heating element. Instep 1302, the treatment element is placed in thermal contact with the tissue to be heated, such that heat from the treatment element is transferred to the tissue to be heated. - In
step 1303, a maximum temperature provided by the treatment element is controlled, such that the temperature experienced by the drug (that is, in the environment of the drug) does not exceed the limiting temperature sustainable by the drug before degradation occurs. In some embodiments, he maximum temperature can be calibrated for each drug and/or class of drugs. For example, for some types of insulin, the limiting temperature is about 37° C. - In some embodiments, such control can be provided through a microprocessor or other processor for controlling the temperature output by a heating element. A sensor can be provided in order to measure the temperature at and/or near the tissue being heated, in order to determine the temperature experienced by the drug.
- The treatment element includes one or more materials capable of generating an exothermic reaction, in which the amount of such materials and/or ratio can be calculated in order for the temperature of the reaction not to exceed the maximum temperature set for the treatment element based on the desired limiting temperature of the drug. The exothermic reaction can be a heat-generating oxidation reaction, for example, with a mixture of iron powder, activated carbon, salt and water. As can be understood by one skilled in the art, other such mixtures of materials can be used.
- In some embodiments, the treatment element and the drug delivery pen are not disposed in the same housing. However, in such cases the user may forget to apply the treatment to the injection site in some cases, thereby changing the pharmacokinetics, which is undesirable. Therefore, to prevent that the drug delivery pen can include a mechanism for reminding the user to apply the required treatment, before, during or after injecting the drug into the tissue. In some embodiments, the drug delivery pen includes a mechanism that identifies whether the treatment was applied or not and permits drug injection only when the tissue treatment was applied. In some embodiments, the drug delivery pen includes, in addition to the drug injection mechanism, a sensor that indicates whether the treatment was applied or was not applied and a processing unit that enables injection of the drug only when the tissue treatment was applied. Such sensor can be an optical sensor that measures optical properties of the local tissue, or Laser Doppler Flowmeter (“LDF”) that can measure local blood perfusion and identify that the vasodilatation inducing local treatment was applied and that the treatment level was adequate.
- Example embodiments of the methods and components of the present invention have been described herein. As noted elsewhere, these example embodiments have been described for illustrative purposes only, and are not limiting. Other embodiments are possible and are covered by the invention. For example, at the present application many of the suggested methods and devices can be used for many of the drug injection devices, such as injection pens or syringes or jet injector and other known in the art injection devices, so although the examples are mainly given for injection pens they are applied to the other injection devices as well. Such embodiments will be apparent to persons skilled in the relevant art(s) based on the teachings contained herein. Thus, the breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.
- Any and all references to patents, patent applications, articles and other published and non-published documents made in the present disclosure are herein incorporated by reference in their entirety.
Claims (2)
1. An apparatus for delivering therapeutic fluid to a patient at an injection site, comprising:
a fluid injection device having a housing, wherein said housing contains:
an injector for injecting the therapeutic fluid to the injection site; and
a reservoir for containing the therapeutic fluid;
a treatment element coupled to said fluid injection device and configured to apply treatment to the injection site;
wherein said treatment element is further configured to improve pharmacokinetic and/or pharmacodynamics property of the therapeutic fluid.
2-80. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/480,359 US20140378908A1 (en) | 2007-03-19 | 2014-09-08 | Drug delivery device |
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89551807P | 2007-03-19 | 2007-03-19 | |
US89551907P | 2007-03-19 | 2007-03-19 | |
US91269807P | 2007-04-19 | 2007-04-19 | |
US94072107P | 2007-05-30 | 2007-05-30 | |
US11/821,230 US9220837B2 (en) | 2007-03-19 | 2007-06-21 | Method and device for drug delivery |
US827707P | 2007-12-18 | 2007-12-18 | |
US1657107P | 2007-12-25 | 2007-12-25 | |
US1075808P | 2008-01-10 | 2008-01-10 | |
PCT/IB2008/051049 WO2008114223A1 (en) | 2007-03-19 | 2008-03-19 | Drug delivery device |
US45025110A | 2010-01-15 | 2010-01-15 | |
US14/480,359 US20140378908A1 (en) | 2007-03-19 | 2014-09-08 | Drug delivery device |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/450,251 Division US8827979B2 (en) | 2007-03-19 | 2008-03-19 | Drug delivery device |
PCT/IB2008/051049 Division WO2008114223A1 (en) | 2007-03-19 | 2008-03-19 | Drug delivery device |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140378908A1 true US20140378908A1 (en) | 2014-12-25 |
Family
ID=39684452
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/450,251 Active 2029-12-24 US8827979B2 (en) | 2007-03-19 | 2008-03-19 | Drug delivery device |
US14/480,359 Abandoned US20140378908A1 (en) | 2007-03-19 | 2014-09-08 | Drug delivery device |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/450,251 Active 2029-12-24 US8827979B2 (en) | 2007-03-19 | 2008-03-19 | Drug delivery device |
Country Status (11)
Country | Link |
---|---|
US (2) | US8827979B2 (en) |
EP (1) | EP2131900B1 (en) |
JP (2) | JP5731120B2 (en) |
KR (1) | KR20090128499A (en) |
CN (2) | CN104069567A (en) |
AU (2) | AU2008227875B2 (en) |
CA (1) | CA2681398A1 (en) |
IL (2) | IL201044A (en) |
MX (1) | MX2009010000A (en) |
RU (2) | RU2481128C2 (en) |
WO (1) | WO2008114223A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101874868B1 (en) | 2017-02-21 | 2018-07-05 | 마산대학교산학협력단 | An Injectable Solutions Activation appartus of an Injector |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2009010000A (en) * | 2007-03-19 | 2010-03-17 | Insuline Medical Ltd | Drug delivery device. |
US8622991B2 (en) | 2007-03-19 | 2014-01-07 | Insuline Medical Ltd. | Method and device for drug delivery |
US9220837B2 (en) | 2007-03-19 | 2015-12-29 | Insuline Medical Ltd. | Method and device for drug delivery |
US8456301B2 (en) | 2007-05-08 | 2013-06-04 | Abbott Diabetes Care Inc. | Analyte monitoring system and methods |
US8160900B2 (en) | 2007-06-29 | 2012-04-17 | Abbott Diabetes Care Inc. | Analyte monitoring and management device and method to analyze the frequency of user interaction with the device |
US8409133B2 (en) | 2007-12-18 | 2013-04-02 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
US8961458B2 (en) | 2008-11-07 | 2015-02-24 | Insuline Medical Ltd. | Device and method for drug delivery |
US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
EP2482915A4 (en) * | 2009-10-02 | 2014-04-02 | Insuline Medical Ltd | Device and method for drug delivery to a targeted skin layer |
EP2404547A1 (en) | 2010-07-10 | 2012-01-11 | Roche Diagnostics GmbH | Method for preparing the insertion of an insertion needle into subcutaneous fatty tissue and insertion device for same |
DE102010046560A1 (en) * | 2010-09-27 | 2012-03-29 | Ludger Schröder | Device for injecting an active substance |
US8301238B2 (en) * | 2011-03-31 | 2012-10-30 | Incline Therapeutics, Inc. | Two-part electrotransport device |
BR112013028858A2 (en) | 2011-05-10 | 2017-01-31 | Insuline Medical Ltd | device for facilitating drug delivery with syringe-based devices, system for facilitating and managing drug delivery data from a plurality of syringe-based drug delivery devices, method for optimizing drug delivery with a device for administration of syringe-based drug with the system |
US20140213976A1 (en) * | 2011-05-30 | 2014-07-31 | Insuline Medical Ltd | Drug Delivery Infusion Set with Manual Pump |
GB2493712B (en) * | 2011-08-12 | 2014-07-02 | Gene Onyx Ltd | Insulin pump |
US9092559B2 (en) * | 2011-08-16 | 2015-07-28 | Ethicon Endo-Surgery, Inc. | Drug delivery system with open architectural framework |
JP6424089B2 (en) | 2011-11-07 | 2018-11-14 | イーライ リリー アンド カンパニー | Injection device with ergonomic improvement |
US20140324021A1 (en) * | 2011-11-07 | 2014-10-30 | Eli Lilly And Company | Medicinal patch and injector system |
US9572931B2 (en) | 2012-06-26 | 2017-02-21 | Ambu A/S | Device, system and method for self-administration of a treatment fluid |
US9795740B2 (en) | 2012-10-12 | 2017-10-24 | Eli Lilly And Company | Chemical engines and methods for their use, especially in the injection of highly viscous fluids |
US9321581B2 (en) | 2012-10-12 | 2016-04-26 | Eli Lilly And Company | Process and device for delivery of fluid by chemical reaction |
FR2999438B1 (en) * | 2012-12-15 | 2015-12-11 | Stephane Decaux | CAPSULE AND DEVICE FOR DISTRIBUTING A PRODUCT WITH TRANSMISSION OF ENERGY RADIATION IN THE FORM OF LUMINOUS ONDULATORY FORM |
US20140257204A1 (en) * | 2013-03-05 | 2014-09-11 | Stuart Robert Lessin | Apparatus for reconstituting and dispensing drugs for topical application |
DE202013101276U1 (en) * | 2013-03-25 | 2013-04-08 | Pfm Medical Ag | Device for the introduction of objects |
CA2926110C (en) | 2013-10-24 | 2023-05-23 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
US10335556B2 (en) | 2013-12-06 | 2019-07-02 | Genentech, Inc. | Apparatus and methods for low-volume medicament delivery |
WO2015153899A1 (en) * | 2014-04-02 | 2015-10-08 | Zogenix, Inc. | Kits for drug delivery site preparation |
JP2016007259A (en) * | 2014-06-23 | 2016-01-18 | オリンパス株式会社 | Medical device |
CN208591401U (en) * | 2015-06-30 | 2019-03-12 | 美佳境植牙股份有限公司 | Drug injecting device |
CN107320177A (en) * | 2016-04-29 | 2017-11-07 | 周星 | Radio-frequency ablation electrode and system with local infiltration anesthesia function |
WO2018004182A1 (en) * | 2016-06-30 | 2018-01-04 | 서울대학교 산학협력단 | Biosensing device and drug delivery device |
US20180028755A1 (en) * | 2016-07-28 | 2018-02-01 | Portal Instruments, Inc. | Connected health platform including needle-free injector system |
KR101684250B1 (en) * | 2016-11-10 | 2016-12-08 | 전진우 | Needle-less drug delivery system |
KR101905830B1 (en) * | 2016-11-15 | 2018-10-08 | 울산과학기술원 | Cryoanesthesia device, method for controlling cryoanesthesia device and temperature controller of coolant in cryoanesthesia device |
AU2018220724A1 (en) | 2017-02-17 | 2019-07-11 | Eli Lilly And Company | Processes and devices for delivery of fluid by chemical reaction |
KR101887088B1 (en) * | 2017-02-28 | 2018-08-09 | (주)강앤박메디컬 | Needle free solution injecting apparatus and method of needle free injecting solution using the same |
US10413658B2 (en) | 2017-03-31 | 2019-09-17 | Capillary Biomedical, Inc. | Helical insertion infusion device |
US11833333B2 (en) | 2017-07-12 | 2023-12-05 | Insuline Medical Ltd | Drug tracking device |
USD869647S1 (en) * | 2018-01-22 | 2019-12-10 | Joshua Dorsey | Syringe |
CN110025856A (en) * | 2019-05-08 | 2019-07-19 | 吉林大学 | A kind of Painless Muscle Injection pump with heating massage function |
CN111973267B (en) * | 2020-09-27 | 2021-09-24 | 张海民 | Microwave ablation needle capable of controlling injection metering |
KR102603796B1 (en) * | 2021-08-20 | 2023-11-20 | 이석제 | Smart insulin injection device with blood glucose measurement |
WO2023027250A1 (en) * | 2021-08-23 | 2023-03-02 | 이석제 | Smart insulin-injecting device capable of measuring blood sugar |
Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4010749A (en) * | 1975-05-09 | 1977-03-08 | Shaw Robert F | Method of detecting infiltration of infused liquid by comparing altered skin temperature with skin temperature in area of infiltrated liquid |
US5222362A (en) * | 1989-01-10 | 1993-06-29 | Maus Daryl D | Heat-activated drug delivery system and thermal actuators therefor |
US20020040208A1 (en) * | 2000-10-04 | 2002-04-04 | Flaherty J. Christopher | Data collection assembly for patient infusion system |
US6461329B1 (en) * | 2000-03-13 | 2002-10-08 | Medtronic Minimed, Inc. | Infusion site leak detection system and method of using the same |
US6508785B1 (en) * | 1998-03-06 | 2003-01-21 | Spectrx, Inc. | Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue |
US6589229B1 (en) * | 2000-07-31 | 2003-07-08 | Becton, Dickinson And Company | Wearable, self-contained drug infusion device |
US20030130616A1 (en) * | 1999-06-03 | 2003-07-10 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US20030138464A1 (en) * | 1995-07-28 | 2003-07-24 | Jie Zhang | Method and apparatus for improved heat controlled administration of pharmaceuticals |
US20040030282A1 (en) * | 2002-08-09 | 2004-02-12 | Toby Freyman | Injection devices that provide reduced outflow of therapeutic agents and methods of delivering therapeutic agents |
US20040171518A1 (en) * | 2003-02-27 | 2004-09-02 | Medtronic Minimed, Inc. | Compounds for protein stabilization and methods for their use |
US20040210280A1 (en) * | 2002-10-25 | 2004-10-21 | Bionics Pharma Gmbh | Plaster-type chip systems for thermodynamic control of topical dermal and transdermal systems |
US20050009735A1 (en) * | 2001-06-28 | 2005-01-13 | Medtronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulation derived therefrom |
US20050182307A1 (en) * | 2000-06-01 | 2005-08-18 | Science Applications International Corporation | Systems and methods for monitoring health and delivering drugs transdermally |
US20050182389A1 (en) * | 2001-04-30 | 2005-08-18 | Medtronic, Inc | Implantable medical device and patch system and method of use |
US20060030838A1 (en) * | 2004-07-02 | 2006-02-09 | Gonnelli Robert R | Methods and devices for delivering GLP-1 and uses thereof |
US20060135911A1 (en) * | 2004-12-17 | 2006-06-22 | Aravindkumar Mittur | Temperature modulation of transdermal drug delivery |
US7083580B2 (en) * | 2001-04-06 | 2006-08-01 | Mattioli Engineering Ltd. | Method and apparatus for skin absorption enhancement and transdermal drug delivery |
US20060271020A1 (en) * | 2005-05-24 | 2006-11-30 | Huang Joseph Z | Portable drug delivery device including a detachable and replaceble administration or dosing element |
US20080061961A1 (en) * | 2005-08-31 | 2008-03-13 | John Michael S | Methods and Systems for semi-automatic adjustment of medical monitoring and treatment. |
US20080281297A1 (en) * | 2007-03-19 | 2008-11-13 | Benny Pesach | Method and device for drug delivery |
US20100152644A1 (en) * | 2007-03-19 | 2010-06-17 | Insuline Medical Ltd. | Method and device for drug delivery |
US20100174225A1 (en) * | 2007-03-19 | 2010-07-08 | Benny Pesach | Drug delivery device |
US9387033B2 (en) * | 2008-08-28 | 2016-07-12 | Roche Diabetes Care, Inc. | Device and method for enhanced subcutaneous insulin absorption |
Family Cites Families (374)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US645648A (en) * | 1898-11-30 | 1900-03-20 | Electric Haulage And Mfg Company | Electric railway. |
US3620209A (en) | 1970-05-08 | 1971-11-16 | Harvey Kravitz | Device for reducing the pain of injections of medicines and other biologicals |
US3683911A (en) | 1970-08-13 | 1972-08-15 | Pelam Inc | Protective seal for catheter |
US4230105A (en) | 1978-11-13 | 1980-10-28 | Merck & Co., Inc. | Transdermal delivery of drugs |
US4628928A (en) | 1982-08-09 | 1986-12-16 | Medtronic, Inc. | Robotic implantable medical device and/or component restoration system |
US4771772A (en) | 1982-08-09 | 1988-09-20 | Medtronic, Inc. | Robotic implantable medical device and/or component restoration system |
JPS60174716A (en) | 1984-02-21 | 1985-09-09 | Yamanouchi Pharmaceut Co Ltd | Medicinal patch |
USH71H (en) | 1984-08-03 | 1986-06-03 | Medtronic, Inc. | Apparatus and method for indication of iontophoretic drug dispenser operability |
US4747819A (en) | 1984-10-29 | 1988-05-31 | Medtronic, Inc. | Iontophoretic drug delivery |
US5135477A (en) | 1984-10-29 | 1992-08-04 | Medtronic, Inc. | Iontophoretic drug delivery |
US4744787A (en) | 1984-10-29 | 1988-05-17 | Medtronic, Inc. | Iontophoresis apparatus and methods of producing same |
US4948587A (en) | 1986-07-08 | 1990-08-14 | Massachusetts Institute Of Technology | Ultrasound enhancement of transbuccal drug delivery |
EP0258521B1 (en) | 1986-08-23 | 1990-05-02 | Arno Walter Latzke | Means for applying media by percutany |
JPH01122037U (en) | 1988-02-12 | 1989-08-18 | ||
US5243986A (en) | 1988-04-30 | 1993-09-14 | Richard Wolf Gmbh | Dissolution of concretions in a bodily cavity |
US4998930A (en) | 1988-08-03 | 1991-03-12 | Phototherapeutic Systems | Intracavity laser phototherapy method |
DE3831809A1 (en) | 1988-09-19 | 1990-03-22 | Funke Hermann | DEVICE DETERMINED AT LEAST PARTLY IN THE LIVING BODY |
US5332577A (en) | 1988-12-27 | 1994-07-26 | Dermamed | Transdermal administration to humans and animals |
JPH02104058U (en) * | 1989-02-03 | 1990-08-17 | ||
DK134189D0 (en) * | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | INSULIN COMPOUNDS |
US4987897A (en) | 1989-09-18 | 1991-01-29 | Medtronic, Inc. | Body bus medical device communication system |
US5324521A (en) | 1989-12-18 | 1994-06-28 | Dermamed | Systems for transdermal administration of medicaments |
US5047007A (en) | 1989-12-22 | 1991-09-10 | Medtronic, Inc. | Method and apparatus for pulsed iontophoretic drug delivery |
US5545208A (en) | 1990-02-28 | 1996-08-13 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US6004346A (en) | 1990-02-28 | 1999-12-21 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
WO1991015260A1 (en) | 1990-03-30 | 1991-10-17 | Alza Corporation | Device and method for iontophoretic drug delivery |
US5213568A (en) | 1990-03-30 | 1993-05-25 | Medtronic Inc. | Activity controlled electrotransport drug delivery device |
US5098429A (en) | 1990-04-17 | 1992-03-24 | Mmtc, Inc. | Angioplastic technique employing an inductively-heated ferrite material |
US5053033A (en) | 1990-10-10 | 1991-10-01 | Boston Advanced Technologies, Inc. | Inhibition of restenosis by ultraviolet radiation |
US5354324A (en) | 1990-10-18 | 1994-10-11 | The General Hospital Corporation | Laser induced platelet inhibition |
US5527292A (en) | 1990-10-29 | 1996-06-18 | Scimed Life Systems, Inc. | Intravascular device for coronary heart treatment |
US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
US5271736A (en) | 1991-05-13 | 1993-12-21 | Applied Medical Research | Collagen disruptive morphology for implants |
CA2073750C (en) | 1991-07-18 | 1996-11-12 | Toshiaki Yutori | Catheter guide wire and catheter |
DE4227800C2 (en) | 1991-08-21 | 1996-12-19 | Toshiba Kawasaki Kk | Thrombus-releasing treatment device |
US5411550A (en) | 1991-09-16 | 1995-05-02 | Atrium Medical Corporation | Implantable prosthetic device for the delivery of a bioactive material |
US5871446A (en) | 1992-01-10 | 1999-02-16 | Wilk; Peter J. | Ultrasonic medical system and associated method |
JPH07508185A (en) | 1992-04-03 | 1995-09-14 | マイクロメディカル・インダストリーズ・リミテッド | Sensors and systems for physiological monitoring |
EP0649316B2 (en) | 1992-10-15 | 2013-08-28 | The General Hospital Corporation | An infusion pump with an electronically loadable drug library |
US5383873A (en) | 1992-12-09 | 1995-01-24 | Regents Of The University Of Minnesota | Smooth muscle chemical pacemaker |
US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
GB9319429D0 (en) | 1993-09-21 | 1993-11-03 | London Health Ass | Methods and products for controlling immune responses in mammals |
US6133242A (en) | 1993-10-15 | 2000-10-17 | Thomas Jefferson Univerisity | Inhibition of extracellular matrix synthesis by antisense compounds directed to nuclear proto-oncogenes |
US6323184B1 (en) | 1993-10-15 | 2001-11-27 | Thomas Jefferson University | Arteriovenous and venous graft treatments: methods and compositions |
US5567592A (en) | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
US5697975A (en) | 1994-02-09 | 1997-12-16 | The University Of Iowa Research Foundation | Human cerebral cortex neural prosthetic for tinnitus |
SE9400823D0 (en) | 1994-03-10 | 1994-03-10 | Siemens Elema Ab | Procedure for catheter cleaning in implanted drug infusion system |
US6056744A (en) | 1994-06-24 | 2000-05-02 | Conway Stuart Medical, Inc. | Sphincter treatment apparatus |
US5556421A (en) | 1995-02-22 | 1996-09-17 | Intermedics, Inc. | Implantable medical device with enclosed physiological parameter sensors or telemetry link |
US5571152A (en) | 1995-05-26 | 1996-11-05 | Light Sciences Limited Partnership | Microminiature illuminator for administering photodynamic therapy |
US5995860A (en) | 1995-07-06 | 1999-11-30 | Thomas Jefferson University | Implantable sensor and system for measurement and control of blood constituent levels |
US6284266B1 (en) | 1995-07-28 | 2001-09-04 | Zars, Inc. | Methods and apparatus for improved administration of fentanyl and sufentanil |
US6756053B2 (en) | 1995-07-28 | 2004-06-29 | Zars, Inc. | Controlled heat induced rapid delivery of pharmaceuticals from skin depot |
US5658583A (en) | 1995-07-28 | 1997-08-19 | Zhang; Jie | Apparatus and methods for improved noninvasive dermal administration of pharmaceuticals |
US6377846B1 (en) | 1997-02-21 | 2002-04-23 | Medtronic Ave, Inc. | Device for delivering localized x-ray radiation and method of manufacture |
US5741211A (en) | 1995-10-26 | 1998-04-21 | Medtronic, Inc. | System and method for continuous monitoring of diabetes-related blood constituents |
US5590657A (en) | 1995-11-06 | 1997-01-07 | The Regents Of The University Of Michigan | Phased array ultrasound system and method for cardiac ablation |
US6766183B2 (en) | 1995-11-22 | 2004-07-20 | Medtronic Minimed, Inc. | Long wave fluorophore sensor compounds and other fluorescent sensor compounds in polymers |
US6350276B1 (en) * | 1996-01-05 | 2002-02-26 | Thermage, Inc. | Tissue remodeling apparatus containing cooling fluid |
US6904318B2 (en) | 2000-09-26 | 2005-06-07 | Medtronic, Inc. | Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure |
US6532388B1 (en) | 1996-04-30 | 2003-03-11 | Medtronic, Inc. | Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure |
US6735471B2 (en) | 1996-04-30 | 2004-05-11 | Medtronic, Inc. | Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure |
US6628987B1 (en) | 2000-09-26 | 2003-09-30 | Medtronic, Inc. | Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia |
US6449507B1 (en) | 1996-04-30 | 2002-09-10 | Medtronic, Inc. | Method and system for nerve stimulation prior to and during a medical procedure |
WO1997043448A2 (en) | 1996-05-13 | 1997-11-20 | G.D. Searle & Co. | Analysis of expression of rat cytochrome p450 isoenzymes and phase ii conjugating enzymes |
US6068623A (en) | 1997-03-06 | 2000-05-30 | Percusurge, Inc. | Hollow medical wires and methods of constructing same |
US5906636A (en) | 1996-09-20 | 1999-05-25 | Texas Heart Institute | Heat treatment of inflamed tissue |
EP0835673A3 (en) | 1996-10-10 | 1998-09-23 | Schneider (Usa) Inc. | Catheter for tissue dilatation and drug delivery |
US7101857B2 (en) | 1996-11-05 | 2006-09-05 | Gp Medical, Inc. | Crosslinkable biological material and medical uses |
US6913763B2 (en) | 1996-11-19 | 2005-07-05 | Intrabrain International Nv | Method and device for enhanced delivery of a biologically active agent through the spinal spaces into the central nervous system of a mammal |
US5725017A (en) | 1997-01-27 | 1998-03-10 | Medtronic, Inc. | In-line pressure check valve for drug-delivery systems |
US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
DE19717107B4 (en) | 1997-04-23 | 2005-06-23 | Disetronic Licensing Ag | System of container and drive device for a piston, which is held in the container containing a drug fluid |
US6061587A (en) | 1997-05-15 | 2000-05-09 | Regents Of The University Of Minnesota | Method and apparatus for use with MR imaging |
US6026316A (en) | 1997-05-15 | 2000-02-15 | Regents Of The University Of Minnesota | Method and apparatus for use with MR imaging |
US5882332A (en) | 1997-06-06 | 1999-03-16 | Wijay; Bandula | Drug infusion catheter and method |
US5919216A (en) | 1997-06-16 | 1999-07-06 | Medtronic, Inc. | System and method for enhancement of glucose production by stimulation of pancreatic beta cells |
US6093167A (en) | 1997-06-16 | 2000-07-25 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
RU2147893C1 (en) * | 1997-07-28 | 2000-04-27 | Новосибирский государственный технический университет | Device for carrying out cavitary actions |
EP0895753A1 (en) | 1997-07-31 | 1999-02-10 | Academisch Ziekenhuis Utrecht | Temporary vascular seal for anastomosis |
US6060454A (en) | 1997-08-08 | 2000-05-09 | Duke University | Compositions, apparatus and methods for facilitating surgical procedures |
US6711436B1 (en) | 1997-08-08 | 2004-03-23 | Duke University | Compositions, apparatus and methods for facilitating surgical procedures |
ES2227880T3 (en) | 1997-08-09 | 2005-04-01 | Roche Diagnostics Gmbh | ANALYSIS DEVICE FOR PERFORMING LIVE ANALYSIS IN A PATIENT'S BODY. |
US6125291A (en) | 1998-10-30 | 2000-09-26 | Medtronic, Inc. | Light barrier for medical electrical lead oxygen sensor |
US6125290A (en) | 1998-10-30 | 2000-09-26 | Medtronic, Inc. | Tissue overgrowth detector for implantable medical device |
US6198952B1 (en) | 1998-10-30 | 2001-03-06 | Medtronic, Inc. | Multiple lens oxygen sensor for medical electrical lead |
US6144866A (en) | 1998-10-30 | 2000-11-07 | Medtronic, Inc. | Multiple sensor assembly for medical electric lead |
US6134459A (en) | 1998-10-30 | 2000-10-17 | Medtronic, Inc. | Light focusing apparatus for medical electrical lead oxygen sensor |
US6247812B1 (en) | 1997-09-25 | 2001-06-19 | Vismed | System and method for diagnosing and treating a target tissue |
US6342250B1 (en) | 1997-09-25 | 2002-01-29 | Gel-Del Technologies, Inc. | Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices |
DE19746377C1 (en) | 1997-10-21 | 1999-07-01 | Fresenius Medical Care De Gmbh | Blood treatment device with a device for continuous monitoring of the patient's blood pressure |
US6156029A (en) | 1997-11-25 | 2000-12-05 | Eclipse Surgical Technologies, Inc. | Selective treatment of endocardial/myocardial boundary |
US6117643A (en) | 1997-11-25 | 2000-09-12 | Ut Battelle, Llc | Bioluminescent bioreporter integrated circuit |
NZ504879A (en) | 1997-12-04 | 2003-05-30 | Roche Diagnostics Corp | Instrument for engaging a power cell |
US6305381B1 (en) | 1998-02-02 | 2001-10-23 | Medtronic Inc. | System for locating implantable medical device |
US6296630B1 (en) | 1998-04-08 | 2001-10-02 | Biocardia, Inc. | Device and method to slow or stop the heart temporarily |
US6210368B1 (en) | 1998-04-30 | 2001-04-03 | Medtronic, Inc. | Reservoir volume sensors |
US6161047A (en) | 1998-04-30 | 2000-12-12 | Medtronic Inc. | Apparatus and method for expanding a stimulation lead body in situ |
TW406018B (en) | 1998-05-21 | 2000-09-21 | Elan Corp Plc | Improved adhesive system for medical devices |
US6736797B1 (en) | 1998-06-19 | 2004-05-18 | Unomedical A/S | Subcutaneous infusion set |
US6554798B1 (en) | 1998-08-18 | 2003-04-29 | Medtronic Minimed, Inc. | External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities |
DE19840965A1 (en) | 1998-09-08 | 2000-03-09 | Disetronic Licensing Ag | Device for self-administration of a product fluid |
WO2000018339A1 (en) * | 1998-09-29 | 2000-04-06 | Zars, Inc. | Methods and apparatus for improved administration of pharmaceutically active compounds |
US6955819B2 (en) | 1998-09-29 | 2005-10-18 | Zars, Inc. | Methods and apparatus for using controlled heat to regulate transdermal and controlled release delivery of fentanyl, other analgesics, and other medical substances |
US6726673B1 (en) | 1999-05-24 | 2004-04-27 | Zars, Inc. | Methods and apparatus for improved administration of testosterone pharmaceuticals |
GB9822150D0 (en) | 1998-10-09 | 1998-12-02 | Dignes Roy | Ultrasound driven devices for accelerated transfer of substances across porous boundaries |
DE59912588D1 (en) | 1998-10-16 | 2005-10-27 | Kolbe Eckhard | PRESSURE JET INJECTOR FOR PAIN-FREE INJECTION OF MEDICAMENTS |
JP4095729B2 (en) | 1998-10-26 | 2008-06-04 | 株式会社日立製作所 | Therapeutic ultrasound system |
US7193521B2 (en) | 1998-10-29 | 2007-03-20 | Medtronic Minimed, Inc. | Method and apparatus for detecting errors, fluid pressure, and occlusions in an ambulatory infusion pump |
US7621893B2 (en) | 1998-10-29 | 2009-11-24 | Medtronic Minimed, Inc. | Methods and apparatuses for detecting occlusions in an ambulatory infusion pump |
US6597946B2 (en) | 1998-11-09 | 2003-07-22 | Transpharma Ltd. | Electronic card for transdermal drug delivery and analyte extraction |
US6312412B1 (en) * | 1998-12-02 | 2001-11-06 | V. C. Saied, M.D. | Apparatus and method for painless intramuscular or subcutaneous injections |
US6955661B1 (en) | 1999-01-25 | 2005-10-18 | Atrium Medical Corporation | Expandable fluoropolymer device for delivery of therapeutic agents and method of making |
US6561978B1 (en) | 1999-02-12 | 2003-05-13 | Cygnus, Inc. | Devices and methods for frequent measurement of an analyte present in a biological system |
US6198966B1 (en) | 1999-02-26 | 2001-03-06 | Medtronic, Inc. | Recirculating implantable drug delivery system |
US6541021B1 (en) | 1999-03-18 | 2003-04-01 | Durect Corporation | Devices and methods for pain management |
US6261280B1 (en) | 1999-03-22 | 2001-07-17 | Medtronic, Inc | Method of obtaining a measure of blood glucose |
US6389313B1 (en) | 1999-03-26 | 2002-05-14 | Kevin S. Marchitto | Laser probes for drug permeation |
US6317615B1 (en) | 1999-04-19 | 2001-11-13 | Cardiac Pacemakers, Inc. | Method and system for reducing arterial restenosis in the presence of an intravascular stent |
US6669663B1 (en) | 1999-04-30 | 2003-12-30 | Medtronic, Inc. | Closed loop medicament pump |
US6228050B1 (en) | 1999-04-30 | 2001-05-08 | Medtronic Inc. | Overfill protection systems for implantable drug delivery devices |
US6152898A (en) | 1999-04-30 | 2000-11-28 | Medtronic, Inc. | Overfill protection systems for implantable drug delivery devices |
US6471675B1 (en) | 1999-04-30 | 2002-10-29 | Medtronic, Inc. | Passive flow control devices for implantable pumps |
US6923784B2 (en) | 1999-04-30 | 2005-08-02 | Medtronic, Inc. | Therapeutic treatment of disorders based on timing information |
US20020168618A1 (en) | 2001-03-06 | 2002-11-14 | Johns Hopkins University School Of Medicine | Simulation system for image-guided medical procedures |
US6458102B1 (en) | 1999-05-28 | 2002-10-01 | Medtronic Minimed, Inc. | External gas powered programmable infusion device |
US7190997B1 (en) | 1999-06-04 | 2007-03-13 | Impulse Dynamics Nv | Drug delivery device |
US7092753B2 (en) | 1999-06-04 | 2006-08-15 | Impulse Dynamics Nv | Drug delivery device |
US7171263B2 (en) | 1999-06-04 | 2007-01-30 | Impulse Dynamics Nv | Drug delivery device |
CA2376128C (en) * | 1999-06-04 | 2009-01-06 | Georgia Tech Research Corporation | Devices and methods for enhanced microneedle penetration of biological barriers |
FR2795629A1 (en) * | 1999-06-11 | 2001-01-05 | Dmds | Portable instrument for producing local anesthesia by effect of cold or heat has thermoelectric elements to cool or heat conducting tip |
US6425853B1 (en) | 1999-06-23 | 2002-07-30 | Stuart D. Edwards | Treating body tissue by applying energy and substances with a retractable catheter and contained cooling element |
US6453648B1 (en) | 1999-07-06 | 2002-09-24 | Zars, Inc. | Method for manufacturing a heat generating apparatus |
US7149773B2 (en) | 1999-07-07 | 2006-12-12 | Medtronic, Inc. | System and method of automated invoicing for communications between an implantable medical device and a remote computer system or health care provider |
US6804558B2 (en) | 1999-07-07 | 2004-10-12 | Medtronic, Inc. | System and method of communicating between an implantable medical device and a remote computer system or health care provider |
US7181505B2 (en) | 1999-07-07 | 2007-02-20 | Medtronic, Inc. | System and method for remote programming of an implantable medical device |
AU6076200A (en) | 1999-07-08 | 2001-01-30 | Johnson & Johnson Consumer Companies, Inc. | Exothermic bandage |
US6471689B1 (en) | 1999-08-16 | 2002-10-29 | Thomas Jefferson University | Implantable drug delivery catheter system with capillary interface |
US6528086B2 (en) | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
US6385491B1 (en) | 1999-10-04 | 2002-05-07 | Medtronic, Inc. | Temporary medical electrical lead having biodegradable electrode mounting pad loaded with therapeutic drug |
US20020095134A1 (en) | 1999-10-14 | 2002-07-18 | Pettis Ronald J. | Method for altering drug pharmacokinetics based on medical delivery platform |
US7063684B2 (en) | 1999-10-28 | 2006-06-20 | Medtronic Minimed, Inc. | Drive system seal |
US6644321B1 (en) | 1999-10-29 | 2003-11-11 | Medtronic, Inc. | Tactile feedback for indicating validity of communication link with an implantable medical device |
US20020026141A1 (en) | 1999-11-04 | 2002-02-28 | Medtronic, Inc. | System for pancreatic stimulation and glucose measurement |
US6925393B1 (en) | 1999-11-18 | 2005-08-02 | Roche Diagnostics Gmbh | System for the extrapolation of glucose concentration |
US6283949B1 (en) | 1999-12-27 | 2001-09-04 | Advanced Cardiovascular Systems, Inc. | Refillable implantable drug delivery pump |
US6961448B2 (en) | 1999-12-30 | 2005-11-01 | Medtronic, Inc. | User authentication in medical device systems |
US6447443B1 (en) | 2001-01-13 | 2002-09-10 | Medtronic, Inc. | Method for organ positioning and stabilization |
US7706882B2 (en) * | 2000-01-19 | 2010-04-27 | Medtronic, Inc. | Methods of using high intensity focused ultrasound to form an ablated tissue area |
US6873268B2 (en) | 2000-01-21 | 2005-03-29 | Medtronic Minimed, Inc. | Microprocessor controlled ambulatory medical apparatus with hand held communication device |
DE60106141T2 (en) | 2000-02-04 | 2005-02-10 | Medtronic, Inc., Minneapolis | INFORMATION OBSERVATION DEVICE FOR MEDICAL DEVICE |
GB0003197D0 (en) | 2000-02-11 | 2000-04-05 | Aid Medic Ltd | Improvements in and relating to controlling drug delivery |
US20030060765A1 (en) | 2000-02-16 | 2003-03-27 | Arthur Campbell | Infusion device menu structure and method of using the same |
US6458118B1 (en) | 2000-02-23 | 2002-10-01 | Medtronic, Inc. | Drug delivery through microencapsulation |
US6261595B1 (en) | 2000-02-29 | 2001-07-17 | Zars, Inc. | Transdermal drug patch with attached pocket for controlled heating device |
US6572542B1 (en) | 2000-03-03 | 2003-06-03 | Medtronic, Inc. | System and method for monitoring and controlling the glycemic state of a patient |
DE10011284B4 (en) | 2000-03-08 | 2007-06-28 | Disetronic Licensing Ag | Apparatus for in vivo measurement of the concentration of an ingredient of a body fluid |
US6613082B2 (en) | 2000-03-13 | 2003-09-02 | Jun Yang | Stent having cover with drug delivery capability |
US6379382B1 (en) | 2000-03-13 | 2002-04-30 | Jun Yang | Stent having cover with drug delivery capability |
EP1267986B1 (en) | 2000-03-31 | 2006-05-10 | Medtronic, Inc. | Deflection Mechanism |
US6836687B2 (en) | 2000-03-31 | 2004-12-28 | Medtronic, Inc. | Method and system for delivery of a medical electrical lead within a venous system |
US6733500B2 (en) | 2000-03-31 | 2004-05-11 | Medtronic, Inc. | Method and system for delivering a medical electrical lead within a venous system |
US6626862B1 (en) | 2000-04-04 | 2003-09-30 | Acist Medical Systems, Inc. | Fluid management and component detection system |
US6456883B1 (en) | 2000-04-26 | 2002-09-24 | Medtronic, Inc. | Apparatus and method for allowing immediate retrieval for information and identification from an implantable medical device having a depleted power source |
US6482214B1 (en) | 2000-04-27 | 2002-11-19 | Medtronic, Inc. | Intravascular seal with mesh reinforcement and method for using same |
US6558382B2 (en) | 2000-04-27 | 2003-05-06 | Medtronic, Inc. | Suction stabilized epicardial ablation devices |
WO2001082811A1 (en) | 2000-04-27 | 2001-11-08 | Medtronic, Inc. | System and method for assessing transmurality of ablation lesions |
US6823213B1 (en) | 2000-04-28 | 2004-11-23 | Medtronic, Inc. | Implantable medical device and method using integrated T-wave alternans analyzer |
US6238367B1 (en) | 2000-04-28 | 2001-05-29 | Medtronic, Inc. | Electrical connector for transducer of implantable drug infusion device |
US6572583B1 (en) | 2000-04-28 | 2003-06-03 | Medtronic, Inc. | Bulkhead for implantable infusion device |
US6645176B1 (en) | 2000-04-28 | 2003-11-11 | Medtronic, Inc. | Spring loaded implantable drug infusion device |
US6592519B1 (en) | 2000-04-28 | 2003-07-15 | Medtronic, Inc. | Smart microfluidic device with universal coating |
US6626867B1 (en) | 2000-04-28 | 2003-09-30 | Medtronic, Inc. | Implantable drug infusion device with peristaltic pump using tube guides |
US6485464B1 (en) | 2000-04-28 | 2002-11-26 | Medtronic, Inc. | Reduced height implantable drug infusion device |
US6551346B2 (en) | 2000-05-17 | 2003-04-22 | Kent Crossley | Method and apparatus to prevent infections |
US6537242B1 (en) * | 2000-06-06 | 2003-03-25 | Becton, Dickinson And Company | Method and apparatus for enhancing penetration of a member for the intradermal sampling or administration of a substance |
US20020068869A1 (en) | 2000-06-27 | 2002-06-06 | Axel Brisken | Drug delivery catheter with internal ultrasound receiver |
GB0016507D0 (en) | 2000-07-06 | 2000-08-23 | Medical Res Council | Improvements in or relating to enviromental enrichment of caged animals |
GB0017387D0 (en) | 2000-07-14 | 2000-08-30 | Pfizer Ltd | Novel enzyme |
US6991916B2 (en) | 2000-07-14 | 2006-01-31 | Pfizer Inc. | Compounds for the treatment of sexual dysfunction |
US20050107738A1 (en) | 2000-07-21 | 2005-05-19 | Slater Charles R. | Occludable intravascular catheter for drug delivery and method of using the same |
US20050113798A1 (en) | 2000-07-21 | 2005-05-26 | Slater Charles R. | Methods and apparatus for treating the interior of a blood vessel |
US20030120256A1 (en) | 2001-07-03 | 2003-06-26 | Syntheon, Llc | Methods and apparatus for sclerosing the wall of a varicose vein |
US6605039B2 (en) | 2000-07-24 | 2003-08-12 | Medtronic, Inc. | Cell-based biosensors suitable for implantable medical device applications |
WO2002009647A2 (en) | 2000-07-28 | 2002-02-07 | Emory University | Biological component comprising artificial membrane |
US6633772B2 (en) | 2000-08-18 | 2003-10-14 | Cygnus, Inc. | Formulation and manipulation of databases of analyte and associated values |
US6487446B1 (en) | 2000-09-26 | 2002-11-26 | Medtronic, Inc. | Method and system for spinal cord stimulation prior to and during a medical procedure |
ATE332668T1 (en) | 2000-09-26 | 2006-08-15 | Medtronic Inc | MEDICAL DEVICE FOR BLOOD FLOW CONTROL |
US7024248B2 (en) | 2000-10-16 | 2006-04-04 | Remon Medical Technologies Ltd | Systems and methods for communicating with implantable devices |
US6764446B2 (en) | 2000-10-16 | 2004-07-20 | Remon Medical Technologies Ltd | Implantable pressure sensors and methods for making and using them |
US6628989B1 (en) | 2000-10-16 | 2003-09-30 | Remon Medical Technologies, Ltd. | Acoustic switch and apparatus and methods for using acoustic switches within a body |
US7273457B2 (en) | 2000-10-16 | 2007-09-25 | Remon Medical Technologies, Ltd. | Barometric pressure correction based on remote sources of information |
US6738671B2 (en) | 2000-10-26 | 2004-05-18 | Medtronic, Inc. | Externally worn transceiver for use with an implantable medical device |
US6681135B1 (en) | 2000-10-30 | 2004-01-20 | Medtronic, Inc. | System and method for employing temperature measurements to control the operation of an implantable medical device |
CA2430748A1 (en) | 2000-12-01 | 2002-06-06 | Medtronic, Inc. | Method and apparatus for measurement of mean pulmonary artery pressure form a ventricle in an ambulatory monitor |
US7052483B2 (en) | 2000-12-19 | 2006-05-30 | Animas Corporation | Transcutaneous inserter for low-profile infusion sets |
US6799149B2 (en) | 2000-12-29 | 2004-09-28 | Medtronic, Inc. | Therapy management techniques for an implantable medical device |
US7054782B2 (en) | 2000-12-29 | 2006-05-30 | Medtronic, Inc. | Non-conformance monitoring and control techniques for an implantable medical device |
US6622731B2 (en) | 2001-01-11 | 2003-09-23 | Rita Medical Systems, Inc. | Bone-treatment instrument and method |
US7740623B2 (en) * | 2001-01-13 | 2010-06-22 | Medtronic, Inc. | Devices and methods for interstitial injection of biologic agents into tissue |
US6571125B2 (en) | 2001-02-12 | 2003-05-27 | Medtronic, Inc. | Drug delivery device |
WO2002066986A2 (en) | 2001-02-15 | 2002-08-29 | Medtronic Minimed, Inc. | Polymers functionalized with fluorescent boronate motifs |
US6852694B2 (en) | 2001-02-21 | 2005-02-08 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
US6620151B2 (en) | 2001-03-01 | 2003-09-16 | Advanced Neuromodulation Systems, Inc. | Non-constant pressure infusion pump |
US7244232B2 (en) | 2001-03-07 | 2007-07-17 | Biomed Solutions, Llc | Process for identifying cancerous and/or metastatic cells of a living organism |
US6453195B1 (en) | 2001-03-19 | 2002-09-17 | Medtronic, Inc. | Closed loop drug delivery system and remote management thereof |
US6743204B2 (en) | 2001-04-13 | 2004-06-01 | Medtronic, Inc. | Implantable drug delivery device with peristaltic pump having retracting roller |
US6733476B2 (en) | 2001-04-13 | 2004-05-11 | Medtronic, Inc. | Implantable drug delivery device with peristaltic pump having a bobbin roller assembly |
US6966322B2 (en) | 2001-04-20 | 2005-11-22 | Medtronic, Inc. | Enhanced chronic lead removal |
US6512958B1 (en) | 2001-04-26 | 2003-01-28 | Medtronic, Inc. | Percutaneous medical probe and flexible guide wire |
US6685452B2 (en) | 2001-04-26 | 2004-02-03 | Chris C. Christiansen | Implantable drug delivery pump with desiccant humidity protection |
US6615083B2 (en) | 2001-04-27 | 2003-09-02 | Medtronic, Inc. | Implantable medical device system with sensor for hemodynamic stability and method of use |
US8182527B2 (en) | 2001-05-07 | 2012-05-22 | Cordis Corporation | Heparin barrier coating for controlled drug release |
JP2004533297A (en) | 2001-05-29 | 2004-11-04 | メドトロニック・インコーポレーテッド | Closed loop neuromodulation system for prevention and treatment of heart disease |
US7191008B2 (en) | 2001-05-30 | 2007-03-13 | Medtronic, Inc. | Implantable medical device with a dual power source |
US6697667B1 (en) | 2001-05-31 | 2004-02-24 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for locating coronary sinus |
US6716178B1 (en) | 2001-05-31 | 2004-04-06 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for performing thermal and laser doppler velocimetry measurements |
US7179226B2 (en) | 2001-06-21 | 2007-02-20 | Animas Corporation | System and method for managing diabetes |
US7011630B2 (en) | 2001-06-22 | 2006-03-14 | Animas Technologies, Llc | Methods for computing rolling analyte measurement values, microprocessors comprising programming to control performance of the methods, and analyte monitoring devices employing the methods |
US20030073609A1 (en) * | 2001-06-29 | 2003-04-17 | Pinkerton Thomas C. | Enhanced pharmacokinetic profile of intradermally delivered substances |
US7013177B1 (en) | 2001-07-05 | 2006-03-14 | Advanced Bionics Corporation | Treatment of pain by brain stimulation |
WO2003003915A2 (en) | 2001-07-06 | 2003-01-16 | Optiscan Biomedical | Site selection for determining analyte concentration in living tissue |
US6675049B2 (en) | 2001-07-17 | 2004-01-06 | Medtronic, Inc. | Method and apparatus for automatic implantable medical lead recognition and configuration |
US7094228B2 (en) | 2001-07-31 | 2006-08-22 | Zars, Inc. | Methods and formulations for photodynamic therapy |
US6544212B2 (en) | 2001-07-31 | 2003-04-08 | Roche Diagnostics Corporation | Diabetes management system |
US6928338B1 (en) | 2001-08-10 | 2005-08-09 | Medtronic, Inc. | Decision information system for drug delivery devices |
US20070060864A1 (en) | 2001-08-24 | 2007-03-15 | Redding Bruce K | Skin treatment method and system |
US6962584B1 (en) | 2001-09-06 | 2005-11-08 | Stone Gregg W | Electromagnetic photonic catheter for reducing restenosis |
US7025760B2 (en) | 2001-09-07 | 2006-04-11 | Medtronic Minimed, Inc. | Method and system for non-vascular sensor implantation |
US8506550B2 (en) | 2001-09-07 | 2013-08-13 | Medtronic Minimed, Inc. | Method and system for non-vascular sensor implantation |
US6740072B2 (en) | 2001-09-07 | 2004-05-25 | Medtronic Minimed, Inc. | System and method for providing closed loop infusion formulation delivery |
US6827702B2 (en) | 2001-09-07 | 2004-12-07 | Medtronic Minimed, Inc. | Safety limits for closed-loop infusion pump control |
US6647299B2 (en) | 2001-09-21 | 2003-11-11 | Medtronic, Inc. | Patient programmer for implantable medical device with audio locator signal |
US6728574B2 (en) | 2001-10-19 | 2004-04-27 | Medtronic, Inc. | System and method for patient-controlled relief of pain associated with electrical therapies |
US7176030B2 (en) | 2002-06-17 | 2007-02-13 | O.R. Solutions, Inc. | Method and apparatus for ensuring sterility of disposable medical items used with medical equipment |
US8465466B2 (en) | 2001-10-23 | 2013-06-18 | Medtronic Minimed, Inc | Method and system for non-vascular sensor implantation |
US6758828B2 (en) | 2001-12-10 | 2004-07-06 | Regents Of The University Of Minnesota | Catheter for cell delivery in tissue |
US6723087B2 (en) | 2001-12-14 | 2004-04-20 | Medtronic, Inc. | Apparatus and method for performing surgery on a patient |
US20030144712A1 (en) | 2001-12-20 | 2003-07-31 | Jackson Streeter, M.D. | Methods for overcoming organ transplant rejection |
WO2003054070A2 (en) | 2001-12-20 | 2003-07-03 | Cygnus, Inc. | Highly catalytic screen-printing ink |
CA2473924A1 (en) | 2002-01-23 | 2003-07-31 | Light Sciences Corporation | Systems and methods for photodynamic therapy |
US7033338B2 (en) | 2002-02-28 | 2006-04-25 | Smiths Medical Md, Inc. | Cartridge and rod for axially loading medication pump |
US6852104B2 (en) | 2002-02-28 | 2005-02-08 | Smiths Medical Md, Inc. | Programmable insulin pump |
US6744350B2 (en) | 2002-02-28 | 2004-06-01 | Smiths Medical Md, Inc. | Insulin pump having missed meal bolus alarm |
US7500949B2 (en) | 2002-03-01 | 2009-03-10 | Medtronic Minimed, Inc. | Multilumen catheter |
US6984229B2 (en) | 2002-03-21 | 2006-01-10 | Ceramoptec Industries, Inc. | Device and method for minimizing restenosis after angioplasty treatment |
US6755849B1 (en) | 2002-03-28 | 2004-06-29 | Board Of Regents, The University Of Texas System | Method for delivering energy to tissue and apparatus |
US6912417B1 (en) * | 2002-04-05 | 2005-06-28 | Ichor Medical Systmes, Inc. | Method and apparatus for delivery of therapeutic agents |
US6922585B2 (en) | 2002-04-05 | 2005-07-26 | Medtronic, Inc. | Method and apparatus for predicting recurring ventricular arrhythmias |
US6978174B2 (en) | 2002-04-08 | 2005-12-20 | Ardian, Inc. | Methods and devices for renal nerve blocking |
US7162303B2 (en) | 2002-04-08 | 2007-01-09 | Ardian, Inc. | Renal nerve stimulation method and apparatus for treatment of patients |
US7069078B2 (en) | 2002-04-22 | 2006-06-27 | Medtronic, Inc. | Insulin-mediated glucose uptake monitor |
US6969369B2 (en) | 2002-04-22 | 2005-11-29 | Medtronic, Inc. | Implantable drug delivery system responsive to intra-cardiac pressure |
US7164948B2 (en) | 2002-04-22 | 2007-01-16 | Medtronic, Inc. | Cardiac output measurement using dual oxygen sensors in right and left ventricles |
EA008770B1 (en) | 2002-05-15 | 2007-08-31 | Янссен Фамацевтика Н.В. | N-substituted tricyclic 3-aminopyrazoles as pdgf receptor inhibitors |
US20040127895A1 (en) | 2002-05-20 | 2004-07-01 | Flock Stephen T. | Electromagnetic treatment of tissues and cells |
US7151961B1 (en) | 2002-05-24 | 2006-12-19 | Advanced Bionics Corporation | Treatment of movement disorders by brain stimulation |
US20070083258A1 (en) | 2005-10-06 | 2007-04-12 | Robert Falotico | Intraluminal device and therapeutic agent combination for treating aneurysmal disease |
US7867193B2 (en) | 2004-01-29 | 2011-01-11 | The Charles Stark Draper Laboratory, Inc. | Drug delivery apparatus |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US7314484B2 (en) | 2002-07-02 | 2008-01-01 | The Foundry, Inc. | Methods and devices for treating aneurysms |
US20040014131A1 (en) | 2002-07-09 | 2004-01-22 | Pfizer Inc. | Assay methods |
EP1391794A1 (en) | 2002-07-23 | 2004-02-25 | Novo Nordisk A/S | Device with time indicating means |
US8512276B2 (en) | 2002-07-24 | 2013-08-20 | Medtronic Minimed, Inc. | System for providing blood glucose measurements to an infusion device |
US6929619B2 (en) * | 2002-08-02 | 2005-08-16 | Liebel-Flarshiem Company | Injector |
US6979351B2 (en) | 2002-08-02 | 2005-12-27 | Potencia Medical Ag | Implantable ceramic valve pump assembly |
US7150975B2 (en) | 2002-08-19 | 2006-12-19 | Animas Technologies, Llc | Hydrogel composition for measuring glucose flux |
US7018384B2 (en) | 2002-08-29 | 2006-03-28 | Medtronic, Inc. | Medical passing device and method |
US20040236269A1 (en) | 2002-09-25 | 2004-11-25 | Marchitto Kevin S. | Microsurgical tissue treatment system |
US7736309B2 (en) | 2002-09-27 | 2010-06-15 | Medtronic Minimed, Inc. | Implantable sensor method and system |
US7027856B2 (en) | 2002-09-30 | 2006-04-11 | Medtronic, Inc. | Method for determining a metric of non-sustained arrhythmia occurrence for use in arrhythmia prediction and automatic adjustment of arrhythmia detection parameters |
US7209790B2 (en) | 2002-09-30 | 2007-04-24 | Medtronic, Inc. | Multi-mode programmer for medical device communication |
MXPA05003815A (en) | 2002-10-09 | 2005-07-13 | Compumedics Ltd | Method and apparatus for maintaining and monitoring sleep quality during therapeutic treatments. |
US7027871B2 (en) | 2002-10-31 | 2006-04-11 | Medtronic, Inc. | Aggregation of data from external data sources within an implantable medical device |
US6866678B2 (en) | 2002-12-10 | 2005-03-15 | Interbational Technology Center | Phototherapeutic treatment methods and apparatus |
US7066891B2 (en) | 2002-12-20 | 2006-06-27 | Medtronic, Inc. | Method and apparatus for gauging severity of myocardial ischemic episodes |
ES2288641T3 (en) | 2002-12-20 | 2008-01-16 | Dynogen Pharmaceuticals Inc. | METHOD FOR TREATING PAINFUL DISORDERS OF THE BLADDER USING CALCULATOR MODULATORS OF THE ALFA2-DELTA SUBUNITY. |
US7229288B2 (en) | 2002-12-20 | 2007-06-12 | Medtronic Minimed, Inc. | Method, system, and program for using a virtual environment to provide information on using a product |
US7160252B2 (en) | 2003-01-10 | 2007-01-09 | Medtronic, Inc. | Method and apparatus for detecting respiratory disturbances |
AU2004207010A1 (en) | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Methods of treating lower urinary tract disorders using sodium channel modulators |
WO2004066987A2 (en) | 2003-01-30 | 2004-08-12 | Dynogen Pharmaceuticals, Inc. | Use of sodium channel modulators for treating gastrointestinal tract disorders |
US7149581B2 (en) | 2003-01-31 | 2006-12-12 | Medtronic, Inc. | Patient monitoring device with multi-antenna receiver |
US7162307B2 (en) | 2003-02-11 | 2007-01-09 | Medtronic, Inc. | Channel occupancy in multi-channel medical device communication |
US6915157B2 (en) | 2003-02-18 | 2005-07-05 | Medtronic, Inc. | Implantable medical device for assessing heart failure state from Mechanical Pulsus Alternans |
US6985768B2 (en) | 2003-02-28 | 2006-01-10 | Medtronic, Inc. | Physiological event detection |
US7084116B2 (en) | 2003-03-10 | 2006-08-01 | Dynogen Pharmaceuticals, Inc. | Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators |
US20060264509A1 (en) | 2003-03-21 | 2006-11-23 | Fraser Matthew O | Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators |
US7483750B2 (en) | 2003-03-21 | 2009-01-27 | Second Sight Medical Products, Inc. | Transretinal implant and method of implantation |
DK1492519T3 (en) | 2003-03-21 | 2007-03-05 | Dynogen Pharmaceuticals Inc | Methods for Treating Lower Urinary Tract Disorders Using Alpha-2 Delta Sub-Unit Calcium Channel Modulators with Smooth Muscle Modulators |
US7209784B2 (en) | 2003-03-31 | 2007-04-24 | Medtronic, Inc. | High power implantable battery with improved safety and method of manufacture |
US7186247B2 (en) | 2003-04-04 | 2007-03-06 | Medtronic, Inc. | Apparatus and system for delivery of drug therapies |
EP1539181B1 (en) | 2003-04-04 | 2007-06-27 | Dynogen Pharmaceuticals Inc. | Method of treating lower urinary tract disorders |
US20050008580A1 (en) | 2003-04-09 | 2005-01-13 | Wyeth | Hemophilia treatment by inhalation of coagulation factors |
US8083707B2 (en) | 2003-04-17 | 2011-12-27 | Tosaya Carol A | Non-contact damage-free ultrasonic cleaning of implanted or natural structures having moving parts and located in a living body |
US7187979B2 (en) | 2003-04-25 | 2007-03-06 | Medtronic, Inc. | Medical device synchronization |
US6930602B2 (en) | 2003-04-25 | 2005-08-16 | Medtronic, Inc. | Coaxial cable antenna for communication with implanted medical devices |
US7107093B2 (en) | 2003-04-29 | 2006-09-12 | Medtronic, Inc. | Use of activation and recovery times and dispersions to monitor heart failure status and arrhythmia risk |
US20040220551A1 (en) | 2003-04-30 | 2004-11-04 | Flaherty J. Christopher | Low profile components for patient infusion device |
US20040248979A1 (en) | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
US7254443B2 (en) | 2003-06-06 | 2007-08-07 | Medtronic, Inc. | Implantable medical device including a hermetic connector block extension |
US7125848B2 (en) | 2003-06-13 | 2006-10-24 | Dynogen Pharmaceuticals, Inc. | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators |
US20060276542A1 (en) | 2003-07-10 | 2006-12-07 | Fraser Matthew O | Methods for treating functional bowel disorders using alpha2 subunit calcium channel modulators with smooth muscle modulators |
US7393345B2 (en) * | 2003-07-18 | 2008-07-01 | Chang-Ming Yang | Sterilized safety syringe |
US7534225B2 (en) | 2003-08-07 | 2009-05-19 | Medtronic Minimed, Inc. | Degassing method and system |
US7651488B2 (en) | 2003-09-16 | 2010-01-26 | The Board Of Trustees Of The University Of Illinois | Apparatus and methods for dilating vasospasm of small intracranial arteries |
US8086323B2 (en) | 2003-09-23 | 2011-12-27 | Medtronic Minimed, Inc. | Implantable multi-parameter sensing system and method |
US7206632B2 (en) | 2003-10-02 | 2007-04-17 | Medtronic, Inc. | Patient sensory response evaluation for neuromodulation efficacy rating |
US8034764B2 (en) | 2003-10-21 | 2011-10-11 | Medtronic Minimed, Inc. | Modulation of SOCS expression in therapeutic regimens |
US7309326B2 (en) | 2003-11-18 | 2007-12-18 | Icu Medical, Inc. | Infusion set |
US20050208095A1 (en) | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
US7326721B2 (en) | 2003-12-10 | 2008-02-05 | Hypnion, Inc. | Doxepin analogs and methods of use thereof |
US7482460B2 (en) | 2003-12-10 | 2009-01-27 | Hypnion, Inc. | Doxepin analogs and methods of use thereof |
US7361182B2 (en) | 2003-12-19 | 2008-04-22 | Lightnix, Inc. | Medical lancet |
US7236834B2 (en) | 2003-12-19 | 2007-06-26 | Medtronic, Inc. | Electrical lead body including an in-line hermetic electronic package and implantable medical device using the same |
US8747881B2 (en) | 2003-12-19 | 2014-06-10 | Cordis Corporation | Intraluminal medical devices in combination with therapeutic agents |
US20050249776A1 (en) | 2003-12-19 | 2005-11-10 | Chen Chao C | Coated aneurysmal repair device |
US7846137B2 (en) | 2003-12-26 | 2010-12-07 | Medtronic Minimed, Inc. | Modular catheter system |
AU2003290412A1 (en) * | 2003-12-30 | 2005-07-21 | Council Of Scientific And Industrial Research | Arginine hydrochloride enhances chaperone-like activity of alpha crystallin |
US7840263B2 (en) | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
US20050256499A1 (en) | 2004-03-03 | 2005-11-17 | Pettis Ronald J | Methods and devices for improving delivery of a substance to skin |
US7203541B2 (en) | 2004-03-12 | 2007-04-10 | Medtronic, Inc. | Real-time optimization of right to left ventricular timing sequence in bi-ventricular pacing of heart failure patients |
US7395113B2 (en) | 2004-03-16 | 2008-07-01 | Medtronic, Inc. | Collecting activity information to evaluate therapy |
US7846940B2 (en) | 2004-03-31 | 2010-12-07 | Cordis Corporation | Solution formulations of sirolimus and its analogs for CAD treatment |
US8007737B2 (en) | 2004-04-14 | 2011-08-30 | Wyeth | Use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices |
US20050232965A1 (en) | 2004-04-15 | 2005-10-20 | Robert Falotico | Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque |
US20070051362A1 (en) | 2004-04-23 | 2007-03-08 | Sullivan Timothy R | Multiple unit dose drug delivery system |
US7524864B2 (en) | 2004-04-23 | 2009-04-28 | Hypnion, Inc. | Methods of treating sleep disorders |
US20050267550A1 (en) | 2004-05-28 | 2005-12-01 | Medtronic Minimed, Inc. | System and method for medical communication device and communication protocol for same |
US20050282859A1 (en) | 2004-06-04 | 2005-12-22 | Thor Karl B | Dual acting SNRI-NMDA antagonists for the treatment of genitourinary disorders |
US20060036187A1 (en) | 2004-06-30 | 2006-02-16 | Hester Vos | Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein |
US7344500B2 (en) | 2004-07-27 | 2008-03-18 | Medtronic Minimed, Inc. | Sensing system with auxiliary display |
US8313433B2 (en) * | 2004-08-06 | 2012-11-20 | Medtronic Minimed, Inc. | Medical data management system and process |
US20060063754A1 (en) | 2004-09-21 | 2006-03-23 | Edgar Dale M | Methods of treating a sleep disorder |
ATE542536T1 (en) | 2004-09-21 | 2012-02-15 | Hypnion Inc | 3-Ä4-(DIBENZOÄB,FÜÄ1,4ÜOXAZEPINE-11-YL)-PIPERAZI - 1-YLÜ-2,2-DIMETHYL PROPANOIC ACID FOR USE IN THE TREATMENT OF SLEEP DISORDERS |
EP1809374A4 (en) | 2004-10-12 | 2008-09-10 | Closed Loop Therapies Ltd | Methods and implantable devices for treating supraventricular arrhythmias |
US7563785B2 (en) | 2004-10-29 | 2009-07-21 | Hypnion, Inc. | Quetiapine analogs and methods of use thereof |
SE0402682D0 (en) | 2004-11-04 | 2004-11-04 | Haakan Lagergren Ab | Laser Apparatus for Heat Treatment |
EP1819278A4 (en) | 2004-11-15 | 2009-04-08 | Izex Technologies Inc | Instrumented orthopedic and other medical implants |
US8308794B2 (en) | 2004-11-15 | 2012-11-13 | IZEK Technologies, Inc. | Instrumented implantable stents, vascular grafts and other medical devices |
US20060111704A1 (en) | 2004-11-22 | 2006-05-25 | Rox Medical, Inc. | Devices, systems, and methods for energy assisted arterio-venous fistula creation |
US20060122863A1 (en) | 2004-12-02 | 2006-06-08 | Medtronic, Inc. | Patient management network |
US20060129225A1 (en) | 2004-12-15 | 2006-06-15 | Kopia Gregory A | Device for the delivery of a cardioprotective agent to ischemic reperfused myocardium |
US9636450B2 (en) | 2007-02-19 | 2017-05-02 | Udo Hoss | Pump system modular components for delivering medication and analyte sensing at seperate insertion sites |
US9259175B2 (en) | 2006-10-23 | 2016-02-16 | Abbott Diabetes Care, Inc. | Flexible patch for fluid delivery and monitoring body analytes |
US20080023593A1 (en) | 2005-01-10 | 2008-01-31 | Frank Ritota | AC/DC/DCC model train on board sound module with wireless control |
US7547281B2 (en) | 2005-02-01 | 2009-06-16 | Medtronic Minimed, Inc. | Algorithm sensor augmented bolus estimator for semi-closed loop infusion system |
PL2058020T3 (en) * | 2005-02-01 | 2013-03-29 | Kaleo Inc | Devices for medicament delivery |
WO2006084464A1 (en) | 2005-02-08 | 2006-08-17 | Novo Nordisk A/S | A medical apparatus with a code reader and a method for operating such apparatus |
US7850645B2 (en) | 2005-02-11 | 2010-12-14 | Boston Scientific Scimed, Inc. | Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power |
EP1853158B8 (en) | 2005-02-22 | 2015-06-17 | Admetsys Corporation | Balanced physiological monitoring and treatment system |
US20060293309A1 (en) | 2005-03-28 | 2006-12-28 | Dynogen Pharmaceuticals, Inc. | Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors |
DE602006013115D1 (en) * | 2005-04-26 | 2010-05-06 | Hypnion Inc | BENZISOXAZOLPIPERIDIN COMPOUNDS AND METHOD FOR THE APPLICATION |
US7686787B2 (en) | 2005-05-06 | 2010-03-30 | Medtronic Minimed, Inc. | Infusion device and method with disposable portion |
US20060253085A1 (en) | 2005-05-06 | 2006-11-09 | Medtronic Minimed, Inc. | Dual insertion set |
US20070033074A1 (en) | 2005-06-03 | 2007-02-08 | Medtronic Minimed, Inc. | Therapy management system |
US20060272652A1 (en) | 2005-06-03 | 2006-12-07 | Medtronic Minimed, Inc. | Virtual patient software system for educating and treating individuals with diabetes |
US20070129652A1 (en) | 2005-11-15 | 2007-06-07 | Henry Nita | Methods and apparatus for intracranial ultrasound therapies |
WO2007001624A2 (en) | 2005-06-28 | 2007-01-04 | Microchips, Inc. | Medical and dental implant devices for controlled drug delivery |
US20070016170A1 (en) | 2005-06-29 | 2007-01-18 | Medtronic Minimed, Inc. | Infusion device with bolus alarm deactivation and method of using the same |
JP2009502140A (en) | 2005-07-22 | 2009-01-29 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Photoactivated cation channel and use thereof |
US20070026042A1 (en) | 2005-07-29 | 2007-02-01 | Narayanan Pallasssana V | System for treating aneurysmal disease |
US8998881B2 (en) | 2005-08-10 | 2015-04-07 | Alza Corporation | Method for delivering drugs to tissue under microjet propulsion |
US7737581B2 (en) | 2005-08-16 | 2010-06-15 | Medtronic Minimed, Inc. | Method and apparatus for predicting end of battery life |
US20070048350A1 (en) | 2005-08-31 | 2007-03-01 | Robert Falotico | Antithrombotic coating for drug eluting medical devices |
CA2620943A1 (en) | 2005-09-02 | 2007-03-08 | Iomai Corporation | Devices for transcutaneous delivery of vaccines and transdermal delivery of drugs and uses thereof |
US7713240B2 (en) | 2005-09-13 | 2010-05-11 | Medtronic Minimed, Inc. | Modular external infusion device |
WO2007035658A2 (en) | 2005-09-19 | 2007-03-29 | Lifescan, Inc. | Infusion pumps with a position detector |
US7704226B2 (en) | 2005-11-17 | 2010-04-27 | Medtronic Minimed, Inc. | External infusion device with programmable capabilities to time-shift basal insulin and method of using the same |
EP2338547B1 (en) | 2006-02-09 | 2013-04-17 | DEKA Products Limited Partnership | Fluid delivery systems |
US20080281292A1 (en) * | 2006-10-16 | 2008-11-13 | Hickingbotham Dyson W | Retractable Injection Port |
EP2136863A2 (en) | 2007-03-19 | 2009-12-30 | Insuline Medical Ltd. | Device for drug delivery and associated connections thereto |
US8002752B2 (en) | 2007-06-25 | 2011-08-23 | Medingo, Ltd. | Protector apparatus |
US8409133B2 (en) | 2007-12-18 | 2013-04-02 | Insuline Medical Ltd. | Drug delivery device with sensor for closed-loop operation |
US8961458B2 (en) | 2008-11-07 | 2015-02-24 | Insuline Medical Ltd. | Device and method for drug delivery |
-
2008
- 2008-03-19 MX MX2009010000A patent/MX2009010000A/en active IP Right Grant
- 2008-03-19 CN CN201410136692.2A patent/CN104069567A/en active Pending
- 2008-03-19 CA CA002681398A patent/CA2681398A1/en not_active Abandoned
- 2008-03-19 JP JP2009554119A patent/JP5731120B2/en not_active Expired - Fee Related
- 2008-03-19 US US12/450,251 patent/US8827979B2/en active Active
- 2008-03-19 WO PCT/IB2008/051049 patent/WO2008114223A1/en active Application Filing
- 2008-03-19 AU AU2008227875A patent/AU2008227875B2/en not_active Ceased
- 2008-03-19 EP EP08719774.5A patent/EP2131900B1/en not_active Not-in-force
- 2008-03-19 KR KR1020097021722A patent/KR20090128499A/en active Search and Examination
- 2008-03-19 RU RU2009135627/14A patent/RU2481128C2/en active
- 2008-03-19 CN CN200880016588A patent/CN101678169A/en active Pending
-
2009
- 2009-09-17 IL IL201044A patent/IL201044A/en active IP Right Grant
-
2012
- 2012-04-02 IL IL219001A patent/IL219001A0/en unknown
-
2013
- 2013-01-14 RU RU2013102423/14A patent/RU2013102423A/en not_active Application Discontinuation
- 2013-12-27 JP JP2013271612A patent/JP2014111140A/en active Pending
-
2014
- 2014-06-26 AU AU2014203471A patent/AU2014203471A1/en not_active Abandoned
- 2014-09-08 US US14/480,359 patent/US20140378908A1/en not_active Abandoned
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4010749A (en) * | 1975-05-09 | 1977-03-08 | Shaw Robert F | Method of detecting infiltration of infused liquid by comparing altered skin temperature with skin temperature in area of infiltrated liquid |
US5222362A (en) * | 1989-01-10 | 1993-06-29 | Maus Daryl D | Heat-activated drug delivery system and thermal actuators therefor |
US20030138464A1 (en) * | 1995-07-28 | 2003-07-24 | Jie Zhang | Method and apparatus for improved heat controlled administration of pharmaceuticals |
US6508785B1 (en) * | 1998-03-06 | 2003-01-21 | Spectrx, Inc. | Method and apparatus for enhancing flux rates of a fluid in a microporated biological tissue |
US20030130616A1 (en) * | 1999-06-03 | 2003-07-10 | Medtronic Minimed, Inc. | Closed loop system for controlling insulin infusion |
US6461329B1 (en) * | 2000-03-13 | 2002-10-08 | Medtronic Minimed, Inc. | Infusion site leak detection system and method of using the same |
US20050182307A1 (en) * | 2000-06-01 | 2005-08-18 | Science Applications International Corporation | Systems and methods for monitoring health and delivering drugs transdermally |
US6589229B1 (en) * | 2000-07-31 | 2003-07-08 | Becton, Dickinson And Company | Wearable, self-contained drug infusion device |
US20020040208A1 (en) * | 2000-10-04 | 2002-04-04 | Flaherty J. Christopher | Data collection assembly for patient infusion system |
US7083580B2 (en) * | 2001-04-06 | 2006-08-01 | Mattioli Engineering Ltd. | Method and apparatus for skin absorption enhancement and transdermal drug delivery |
US20050182389A1 (en) * | 2001-04-30 | 2005-08-18 | Medtronic, Inc | Implantable medical device and patch system and method of use |
US20050009735A1 (en) * | 2001-06-28 | 2005-01-13 | Medtronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulation derived therefrom |
US20040030282A1 (en) * | 2002-08-09 | 2004-02-12 | Toby Freyman | Injection devices that provide reduced outflow of therapeutic agents and methods of delivering therapeutic agents |
US20040210280A1 (en) * | 2002-10-25 | 2004-10-21 | Bionics Pharma Gmbh | Plaster-type chip systems for thermodynamic control of topical dermal and transdermal systems |
US20040171518A1 (en) * | 2003-02-27 | 2004-09-02 | Medtronic Minimed, Inc. | Compounds for protein stabilization and methods for their use |
US20060030838A1 (en) * | 2004-07-02 | 2006-02-09 | Gonnelli Robert R | Methods and devices for delivering GLP-1 and uses thereof |
US20060135911A1 (en) * | 2004-12-17 | 2006-06-22 | Aravindkumar Mittur | Temperature modulation of transdermal drug delivery |
US20060271020A1 (en) * | 2005-05-24 | 2006-11-30 | Huang Joseph Z | Portable drug delivery device including a detachable and replaceble administration or dosing element |
US20080061961A1 (en) * | 2005-08-31 | 2008-03-13 | John Michael S | Methods and Systems for semi-automatic adjustment of medical monitoring and treatment. |
US20080281297A1 (en) * | 2007-03-19 | 2008-11-13 | Benny Pesach | Method and device for drug delivery |
US20100152644A1 (en) * | 2007-03-19 | 2010-06-17 | Insuline Medical Ltd. | Method and device for drug delivery |
US20100174225A1 (en) * | 2007-03-19 | 2010-07-08 | Benny Pesach | Drug delivery device |
US9387033B2 (en) * | 2008-08-28 | 2016-07-12 | Roche Diabetes Care, Inc. | Device and method for enhanced subcutaneous insulin absorption |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101874868B1 (en) | 2017-02-21 | 2018-07-05 | 마산대학교산학협력단 | An Injectable Solutions Activation appartus of an Injector |
Also Published As
Publication number | Publication date |
---|---|
MX2009010000A (en) | 2010-03-17 |
US8827979B2 (en) | 2014-09-09 |
EP2131900A1 (en) | 2009-12-16 |
IL201044A0 (en) | 2010-05-17 |
IL219001A0 (en) | 2012-05-31 |
JP5731120B2 (en) | 2015-06-10 |
EP2131900B1 (en) | 2018-05-30 |
US20100174225A1 (en) | 2010-07-08 |
AU2014203471A1 (en) | 2014-07-17 |
AU2008227875B2 (en) | 2014-06-12 |
JP2014111140A (en) | 2014-06-19 |
IL201044A (en) | 2012-05-31 |
CN101678169A (en) | 2010-03-24 |
KR20090128499A (en) | 2009-12-15 |
JP2010522013A (en) | 2010-07-01 |
AU2008227875A1 (en) | 2008-09-25 |
RU2013102423A (en) | 2014-07-20 |
RU2481128C2 (en) | 2013-05-10 |
RU2009135627A (en) | 2011-04-27 |
WO2008114223A1 (en) | 2008-09-25 |
CA2681398A1 (en) | 2008-09-25 |
CN104069567A (en) | 2014-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8827979B2 (en) | Drug delivery device | |
EP2630980B1 (en) | Drug delivery device | |
JP2010522013A5 (en) | ||
US9387033B2 (en) | Device and method for enhanced subcutaneous insulin absorption | |
AU2008227870B2 (en) | Method and device for drug delivery | |
US8622991B2 (en) | Method and device for drug delivery | |
AU2014200298B2 (en) | Method and device for drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |